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1ABSTRACT
Increased programmed ccli death is an important pathological feature
underlying the tissue and organ maffuncifon seen in lysosomal storage
disorders (LSD). Using expression microarrays, differentially expressed genes
that were common to cultured fibroblasts from patients affected with several
different LSDs were identified. These studies, conffrmed by biochemical
experiments, demonsfrated that lysosomal storage is associated with down
regulation of the most abundant cellular ubiquitin C-terminal hydrolase,
UCH-L1 (PGP 9.5), in cultured fibroblasts of patients representing 8 different
LSDs as well as in the brain tissues of a mouse model of Sandhoff disease
with a disrupted hexosaminidase B gene. Induction of lysosomal storage by
treatment of cultured fibroblasts with the lysosomal cysteine protease
inhibitor E-64 reduced UCH-L1 transcripts, protein levels and enzyme
activity. Ail celis and tissues exhibiting lysosomal storage contained
ubiquitinated protein aggregates, and showed reduced levels of free
ubiquitin, decreased proteasomal activity, and increased numbers of
apoptotic celis. The increased rate of apoptosis seen in E64-freated fibroblasts
was reversed by fransient transfection with a UCH-L1 expression vector. In
confrast, siRNA mediated down-regulation of UCH-L1 resulted in high
apoptosis rates with concomitant increase in the expression of pro-apoptotic
proteins such as Bax and p53. Taken together, these data suggest that UCH
Li deficiency and partial impairment of the ubiquitin-dependent protein
degradation pathway may represent a common mechanism for the
pathogenesis of lysosomal storage disorders.
Keywords: Lysosome, proteasome, UCH-Li, ubiquitin, apoptosis, inclusions,
neurodegeneration
2RÉSUMÉ
La mort programmée accrue de cellules est un dispositif pathologique
important sous-tendant les défauts de fonctionnement du tissu et de l’organe
dans les désordres de surcharge lysosomale (SL). Nous montrons que
lapoptose dans les cellules avec de la SL se réalise par l’entremise d’un
affaiblissement partiel de la voie de dégradation ubiquitine-dépendante. En
utilisant des micropuces d’expression, nous avons évalué les changements
secondaires des profils d’ARN messager dans les fibroblastes cultivés de
patients affectés avec plusieurs différentes maladies de SL et avons identifié
les gènes différenfiellement exprimés qui étaient communs à ces conditions.
Ces études, confirmées par des expériences biochimiques, ont démontré que
la SL est associée avec la sous-régulation de la plus abondante hydrolase
d’ubiquitine C-terminale, soit UCH-L1 (PGP 9.5), dans tous les patients
représentant huit désordres de SL différents. Les niveaux de transcrits UCH
Li, de protéine et d’activité ont été également réduits dans des cellules
normales en lesquelles la SL a été induite par l’inhibiteur lysosomal de
cystéine protéases, E-64. Toutes les cellules montrant de la SL contenaient des
agrégats de protéines ubiquitinées, en plus des niveaux réduits d’ubiquitine
libre, inhibition partielle de l’activité du proteasome et un nombre accru de
cellules apoptotiques. Le taux d’apoptose accru observé chez les fibroblastes
traités avec E-64 a pu être reversé lors d’une transfection temporaire avec le
vecteur d’expression pour UCH-L1. D’autre part, la suppression de UCH-L1
par interférence d’ARN dans des fibroblastes normaux a précipité ces
derniers vers l’apoptose avec une élévation concomitante de l’expression des
protéines pro-apoptotiques Bax et p53. Nous speculons que l’insuffisance en
UCH-Li ainsi que la dérégulation partielle de la voie de dégradation
ubiquitine-dépendante représentent un mécanisme commun pour la
pathogénèse des maladies de surcharge lysosomale.
Mots-clés Lysosome, protéasome, UCH-L1, ubiquitine, apoptose, inclusions,
neurodégénération
LITERATURE REVIEW
LYSOSOMAL STORAGE DISORDERS
Cellular composition is determined by the maintenance of a balance
between degradation and synthesis of intracellular components. This
homeostasis can lie perturbed when either process is impaired especially
during adaptive changes, leading to ceil and tissue deregulation. Component
turnover is not only important for the sake of salvaging damaged or
mmecessary by-products, but is also essential in the redirection of ongoing
processes toward new needs. For example, protein degradation rates are
increased during muscle hypertrophy and liver regeneration.
In lysosomal storage disorders (LSD), defects in lysosomal enzymes, in
lysosomal transmembrane fransporters, in hydrolase cofactors or in the
biogenesis of the organelle itseff, causes the sequesfration of the
corresponding unprocessed subsfrates inside the lysosomes and renders
virtually impossible the further reutilization of the monomeric components.
This affects the architecture and function of the celis, tissues and organs
(extralysosomal effects) even though in very few cases the accumulated
substrate may lie directly cytotoxic. The signs associated with LSDs are often
neurological, but cari also lie multisystemic, with skeletal, CNS, cardio
vascular and ocular defects.
The clinical course of these diseases is chronic and progressive, very
often lethal before or in early adulthood. Over 40 types of lysosomal storage
diseases have been identffied, with a collective incidence of 1 in 7000-8000
(Winchester et ai, 2000) live bfrths, and they have been grouped according to
similarities in the biochemistry of accumulated materials, the clinical
presentation and the enzymatic deficiencies. In terms of the storage material,
LSDs can 5e divided into three large groups, the sphingolipidoses, mucopoly
4saccharidoses, glycoproteinoses and several other indïvidual enfities (Table I,
p.8). The inheritance is autosomal recessive for most LSDs, except for MPS II
and Fabry disease. Most of the LSDs can be diagnosed by the assay of
enzymes in circulating leucocytes, biopsy material or cultured skin
flbroblasts. Almost ail of the genes responsible for the variety of LSDs have
been cloned and tMs information is being used for genotype-phenotype
correlation, genetic counseling and selection of patients for novel forms of
therapy.
Endosomat-tysosomat system
Lysosomes are organelles specialized for the infracellular digestion of
macromolecules and are filed with hydrolytic enzymes operating optimally
at an acïdic pH of about 5.0. Lysosomes contain about 40 types of hydrolytic
enzymes or acid hydrolases, including proteases, nucleases, glycosidases,
lipases, phospholipases, phosphatases, and suffatases. The internai pH of the
lysosome is consequently maintained low by an integral lysosomal
membrane ATP-driven hydronium ion (Hj pump. The limilÏng membrane of
the lysosome or late endosome contains also a set of higffly glycosylated
integral membrane proteins, designated as lysosomal-associated membrane
proteins (LAMPs) (such as LAMP-1, LAMP-2, and CD63/LAMP-3),
lysosomal membrane glycoproteins (LGPs) and lysosomal integral membrane
proteins (LIMPs) (Eskelinen et ai, 2003). Additional lysosomal membrane
proteins mediate transport of ions, amino acids, and other solutes across the
lysosomal membrane and contribute to the maintenance of an acidic luminal
pH in the range of 4.6 —5.0. Similar to ail other secretory proteins, lysosomai
enzymes or acid hydrolases are synthesized in the endoplasmic reticulum
and fransported to the Golgi apparatus where ffiey undergo a variety of post
transiational modifications, of which is the aftachment of terminal mannose
56-phosphate groups to specific oligo-saccharide side chains that can 5e
recognized by M6P receptors found on the iimer surface of the Golgi
membrane, and then carried from the trans Goigi network to late endosomes
by means of clathrin-coated transport vesicies.
Lysosomes are morphologically heterogeneous, often resembling other
organelies of the endocytic and secretory pathways including melanosomes,
lytic granules, major histocompatibiity complex (MHC) ciass II
compartments, platelet dense granules, basophil granules, and neutrophil
azurophil granules. Therefore, lysosomes are currently distinguished from
other organelles on the basis of an operational definition, which describes
them as membrane-Sound acidic organelles that contain mature acid
dependent hydrolases and LAMPs, but lack mannose 6-phosphate receptors
(MPRs) (Komfeld and Meilman, 1989).
In ail eukaryotic celis, there are two major pathways of membrane
traffic reaching lysosomes, the endocytic pathway (heterophagy) and
autophagy (Fig. 1, p.6). The former delivers cargo from outside of the cell and
plasma membrane, while the latter transports materials in the cytoplasm and
into lysosomes. Endosomes also relay newiy synthesized lysosomai enzymes
from the secretory pathway to lysosomes (biosynthetic pathway).
It is well known that receptors endocytosed from the plasma
membrane are either recycled to celi surface or transported to lysosomes for
degradation. This sorting event, which takes place in the endosomes, is
critical, since it acts as a filter of cellular signal transduction (Yoshimori,
2002). Ligand-mediated endocytosis is characteristically an early response in
the signaling pathways triggered by a diverse group of cell surface receptors,
including hetero-frimeric guanine nucleotide-bïnding protein (G protein)
coupled receptors (GPCRs), receptor tyrosine kinases (RTKs) and cytokine
receptors.
6fIGURE 1 The lysosomal network.
From the celi surface, the endocytic pathway extends to lysosomes. The biosynthetic pathway
bridges the secretOry paffiway and the endocytic pathway. Autophagy delivers materials
from the cytoplasm to lysosomes. Lysosomes are usually meeting places where severai
streams of infracellular traffic converge. Endocytosed molecules are irdtially delivered in
vesicles to small, irregularly shaped infracellular organelles cafled early endosomes. Some of
these ingested molecules are selectively reftieved and recycled to the plasma membrane,
while offiers pass on into ffie mildly acidic (pH —6) late endosomes to be digested by
lysosomal hydrolases. These are progressively delivered to the endosome from the Goigi
apparatus. Mature lysosomes form from the Iate endosomes, accompanied by a further
decrease in internai pH. Lysosomes are thought to be produced by a graduai maturation
process, during which endosomal membrane proteins are selectiveiy retrieved from ffie
developing lysosome by transport vesicles that deliver these proteins back to endosomes or
the frans Golgi network. A second pathway to degradation in lysosomes is used in ail ceil
types for the disposai of obsolete parts of the ceil itseff, a process called autophagy. The
process seems to begin with ffie enclosure of an organefle by membranes of unknown origin,
creating an autophagosome, which then fuses with a lysosome (or a late endosome).
Professionai phagocytes (macrophages and neutrophils in vertebrates) enguif objects to form
a phagosome, which is then converted to a iysosome in the manner of the autophagosome.
Lysosomai secretion (aiso called defecation) of the undigested contents is a minor paffiway
that enables ail ceils under stress to elirninate indigestibie debris. Some ceil types, however,
contain specialized lysosomes such as melanocytes that have acquired the necessary
machinery for fusion wiffi the plasma membrane.
Plasma membrane
7Concept of tysosomat storage
In general, the distribution of the stored material, and hence which
organs are affected in LSDs, is determined by two interrelated factors: (1) the
tissue where most of the material to 5e degraded is found and (2) the location
where most of the degradation normally occurs (Winchester et ai, 2000). for
example, the brain is rich in glycosphingolipids due to their presence in
neuronal membranes, and hence defective hydrolysis of these molecules, as
occurs in GM1 and GM2 gangliosidoses such as Krabbe, Niemann- Pick and
Gaucher diseases, resuits primarily in storage within neurons and neurologic
symptoms. In contrast, glycosaminoglycans (mucopolysaccharides) are
primarily structural molecules produced by most ceils and are found mainly
on the surface of ceils and in the matrix. Thus, defects in the degradation of
mucopolysaccharides affect vfrtually every organ because they are widely
disfributed in the body. Celis of the mononuclear phagocyte system are
involved in the degradation of a variety of subsfrates through the lysosomal
pathway and organs rich in phagocytic ceils, such as the spleen and liver, are
frequently enlarged in several forms of LSDs.
Normally, LDSs show allelic variation (different mutations of the same
gene) and significant clinical heterogeneity. The severity of the disease, which
influences the time of onset and the pace of the regression, appears to 5e
correlated with the residual enzyme activity, which itself depends on the
nature of the molecular defect (even though clear genotype-phenotype
correlations have often not been established, suggesting the existence of
“modifying” genes). Such a model, elaborated by Conzelmann and Sandhoff
(1983-1984) has found experimental support in several sphingolipidoses.
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9Twenty percent of normal enzyme activity is usually adequate to carry out
cellular function. Consequently, heterozygotes (carriers of LSDs) whose
enzyme activity is about 50 percent of normal are clinically unaffected
(Grabowski and Hopkin, 2003). Symptoms develop when residual enzyme
acffvity falis below a threshold of 15 to 20 percent. Therefore, mutations that
leave no residual enzyme activity cause severe, early-onset illness. Milder
mutations cause insidious, late- or aduit-onset illness. But, what is the link
between (specific) subsfrate storage in the lysosomes and tissue lesions?
Although no well-established mechanism has yet been put forward to answer
this question, it is likely that LSDs are accompanied by dysregulated celi
growth or death.
Patho logical features
Manifestations of neurological deterioration associated with many
LSDs begin in infancy or childhood. Very often it begins with a delay and
then arrest of psychomotor development, neurological regression, buindness,
and seizures. Inexorable progression leads to a vegetative state. LSDs have
diverse and distinct chuical manifestations. Some of them share certain
cili-ilcal and pathological features grouped into four basic clinical-pathological
phenotypes: leukodysfrophy, mucopolysaccharidosis, storage histiocytosis
and neuronal lipidosis, the latter being the most prevalent phenotype (Table
II, p.lO).
The pathology, in the neuronal lipidosis phenotype, primarily involves
the gray matter. Storage causes neuronal ballooning and torpedo-like
swellings of proximal axons and dendrites. This process leads to loss of
neurons and their axons, but myelin is not primarily affected (Neufeld and
Muenzer, 2001). Storage in retinal ganglion ceils causes blindness. Other celis
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and organs that do flot process large amounts of gangliosides are either
normal or show mfld storage without celi damage. The prototype of the
TABLE II OEnicopaffiological LSD phenotypes
PHENOTYPE PATHOLOGY CLINICAL FINDINGS LSDs
NEURONAL UPIDOSIS Storage in the neuronal Neurological regression, Gangliosidoses,
body and processes seizures, blindness mucopolysacchafldoses, neuronal
ceroid Iipofuscinoses
LEUKODYSTROPHY Storage in Neurological regression, Gangliosidoses (metachromatic
oligodendrocytes and spasticity, peripheral Ieukodystrophy, Krabbes disease)
Schwann ceils neuropathy
MUCOPOLYSACCHARIDOSIS Storage in exfraneural Visceromegaly, soft tissue Mucopolysacchafldoses,
tissues swelling, skeletal dyspiasia, glycoproteinoses, GM1
heart disease gangliosidosis
STORAGE HISTIOCYTOSIS Storage in histiocytes Hepatosplenomegaly, Gangliosidoses (Gaucher disease,
hematopoiefic abnormalities Niemann-Pick disease)
neuronal lipidosis phenotype is Tay-Sachs disease, a form of GM2
gangliosisosis prevalent among Ashkenazi Jews, first described more than
100 years ago (Neufeld and Muenzer, 2001). Some LSDs impair enzymes that
are important for turnover of myelin lipids and damage myelin-producing
celis. This results in loss of myelin (leukodystrophy) manifested by
neurological deterioration and spasticity. The mucopolysaccharidoses and
glycoproteinoses affect neurons as well but have also severe skeletal and
visceral manifestations, which constitute the mucopolysaccharidosis
phenotype. In general, the celis that are most severely affected by LSDs are
neurons, because they process large amounts of gangliosides and once lost
they cannot 5e replaced, and histiocytes, because their main function is
lysosomal degradation, and they decompensate if thefr lysosomal enzymes
are deficient. Several LSDs show lipid storage in histiocytes throughout the
lymphoid and hematopoietic tissues. Such storage histiocytosis causes
hepatosplenomegaly, bone manow depression, bone damage and other
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manifestations. In some LSDs, notably Gaucher disease, storage histiocytosis
is the main abnormality.
Cet!utar pathotogy
The major classes of storage diseases can 5e distinguished by the
ulfrastructural appearance of their storage material. Glycosphingolipidoses
present membranous swirls, mucopolysaccharidoses with multilamellar
stacks (“zebra bodies”), fucosidosis and mannosidosis with watery or wispy
material (“open” inclusions), and so forth (Suzuki, 1976). On elecfron
microscopic examination, the stored products are membrane-Sound because
they are contained within lysosomes. The explanation for the characteristic
appearances of storage bodies was that the accumulation of undegraded ceil
material past a certain crifical point was believed to lead to physicochemical
interactions with other components within the lysosome (e.g., cholesterol)
and to formation of the characteristic morphological appearance of the
residual or storage body for a given disease (Suzuki, 1976). Early studies
have shown that residual bodies in storage diseases like Tay-Sachs and other
neurolipïdoses contained acid phosphatase activity, suggesting a lysosomal
status (Walkley, 1998). Arguments that the storage bodies sometimes lacked
histochemical evidence of lysosomal enzymes, or even lysosomal-like
delimiting membranes, and thus might not 5e lysosomal, were eventually
interpreted as simpiy late disease-associated alterations in the lysosome.
Cytotoxicity following mechanical disruption of ceils has often been
invoked as a plausible explanation for the cell dysfunction in lysosomal
diseases. Given the observations that there are ceil-selective consequences of
the storage disease process, it was reasonable to assume that significant extra
lysosomal events are set in motion by deficiencies of single lysosomal
enzymes. At least four possible mechanisms that reach beyond the mere
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mechanical disruption hypothesis can 5e cited (Walkley, 1998): (i) Material
stored within the lysosome may escape and in turn have deieterious effects
elsewhere in the celi, either by direct toxicity or by impinging on other
metabolic pathways to alter celi function. (ii) The massive accumulation of
unprocessed compounds within the lysosome (e.g., gangliosides) may
deprive the celi of certain precursor molecules, leading to a compensatory
upregulafion or dysfunction of other metabolic pathways or organeiles. (iii)
Abnormalffles of the lysosomal system may lead to a reduced entry of
materials into lysosomes and to subsequent increases of this compound
elsewhere in the ceil, with defrimental consequences. For example, plasma
membrane receptor endocytosis is partially disrupted and the related
signaling pathway remains activated. (iv)Defective lysosomai enzyme
activity may adverseiy effect the normal functioning of other related
organelies, most notably endosomes and the whole lysosomal network
dynamics (Fig. 1, p.6).
Generaliy exacerbated apoptosis has been observed in celis or tissues
from patients or animais affected with neurolipidoses; that is, in Tay-Sachs,
Sandhoff (Huang et al, 1997; Wada et ai, 2000), and Krabbe diseases (Taniike
et ai, 1999; Jatana et al, 2002), prosaposin deficiency (Tohyama et al, 1999),
neuronal ceroid iipofuscinoses (Lane et al, 1996) and metachromatic leuko
dysfrophy (Coenen et ai, 2001). Although the molecular mechaiiism of this
increased (neuronal) celi death is not yet estabiished, it has been postulated
that lysosphingoiipids, which accumulate in the affected cells, may mediate
cytotoxicity, possibly through inhibition of protein kinase C (Hannun et ai,
1987). Interestingly, ceiluiar sphingosine ieveis are eievated in Niemann—Pick
disease type C mice, in which increased neuronal ceil death has been also
observed (Wu et ai, 1999). Although the exact contribution of sphingoiipids
to apoptosis needs further characterization (mostly in terms of enzymes
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involved and cellular targets), evidence has accumulated that some of these
lipidic molecules act as bioregulators of ceil growth and death. There is littie
information regarding possible alterations in the apoptotic program in the
visceral forms of lysosomal disorders. Nevertheless, increased apoptosis has
been described in chondrocytes from animais affected with mucopoly
saccharidosis type W (Simonaro et ai, 2001). Cystinotic ceils aiso exhibit an
increased sensffivity to apoptosis (Park et ai, 2002) that might 5e related to the
(thioi-related) redox status of these celis.
Neurons in storage diseases not only exhibit somatic swelling
secondary to accumulation of material, but they reveai a number of other
somatic, dendritic and axonal changes. In Tay-Sachs disease for example,
cortical neurons were described as being swoilen and having enlargements
within the basilar dendrites, but spinal motoneurons only exhibited sweiling
without dendrific changes (Walkley et, 1998). This concept of neuron type
specific changes was extended to the other storage diseases. Two distinct
types of celiular alterations emerged as characteristic of many storage
diseases, namely meganeurites and axonai spheroids. Meganeurites were
parasomatic enlargements within the axon hillock and appeared to occur
secondary to storage as part of a volume expansion by the neuron. They were
found only on certain types of neurons while other types appeared to
undergo simple somatic enlargement secondary to storage. There are realiy
two classes of meganeurites (Walkley et al, 1987; Walkley et al, 1988), named
spiny and aspiny. Spiny and aspiny meganeurites can occur on specific
populations of neurons, whereas in other diseases, like Baffen disease, only
aspiny meganeurites were found. On the other hand, axonal spheroids are
enlargements of the distai segment of the axon that contain storage material
inconsistent with the specific defective lysosomal hydrolase, as opposed to
meganeurite storage material composition. The ultrasfructural appearance of
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spheroid material is the same across many types of storage disorders. The
close similarity of accumulated material in studies of a distai crush or low
temperature lesions in axons to that of spheroids in storage disease (Parton et
ai, 1992) suggests that the latter may be secondary to a block in retrograde
transport. Spheroids are capabie of causing significant interference with the
efficacy or timing of action potential propagation (Walkley et ai, 1991). In
animal models of GM1 and GM2 gangliosidosis, Niemann- Pick disease, CL
mannosidosis, and mucopolysaccharidosis, there is a striking correlation
between the location and incidence of axonal spheroids and the type and
severity of clinical neurological disease (March et ai, 1997).
Anima! modets of tysosomat storage disorders
The animal models of the LSDs should be defined as those in wInch
ffie genes that are orthologous to the genes that cause human lysosomal
disorders are functionally defective. This is to make the distinction with
modeis generated by exogeneous administration of metabolites in high doses
to artificialiy induce a lysosomai storage condition by perturbing the balance
of subsfrate influx over ïts efflux. Although spontaneously occurring genetic
lysosomal storage diseases are as rare in other mammalian species as in man,
the advent of gene targeting technology has revoiutionized the state of
animal models of genetic diseases and neariy ail lysosomal storage diseases
have been duplicated in the mouse (Table III, p.l5). These animal models cari
overcome many of the limitations inherent in studies of human patients such
as rarity of ffie disease, exfremeiy complex genetic background and iogistical
and ethical constraints in the design and execution of experiments with
human subjects.
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TABLE III Non-exhaustive list of mouse models of human LSD
Inacfivated gene Equivalent human disease
Sphingomyelinase Niemann-Pick, types A and B
Glucosylceramidase Gaucher
u-Galactosidase A fabry
Arylsuiphatase A (suiphatidase) Metachromatic Ieukodystrophy (MLD)
P-Hexosaminidase a suburnt Tay-Sachs
-Ga1actosidase GM1-gangliosidosis
[—lrTexesam.i.nidase f.l suhunit Sandhoff
[i-Hexosaminidase u and 3 suhunits Sandhoff
GM2 activator GM2-gangliosidosis AB variant
Sphingolipid activator (prosaposin) Total sphingolipid activator deficïency
3-gal/sialidase protective protein/Cathepsin A Galactosïalidosis
Acid phosphatase Unknown
N-acetyl-Œ-galactosaminidase Schindier
Cation-dependent mannose 6-phosphate receptor Unknown
Cation-mdependent mannose 6-phosphate receptor Unknown
Mannose 6-phosphate receptors, double-knockout Unknown
Acid lipase Wolman disease & cholesteryl ester storage
Lysosomal Œ-neuraminidase Sialidosis
cx4,4-Glucosidase Glycogen storage II
Glucose-6-phosphatase Glycogen storage la
u-Iduronidase Hurler-Scheie fMPS I)
a-N-Acetylglucosaminidase MPS IIIB (Sanfilippos syndrome)
Arylsulphatase B Maroteaux-Lamy (MPS VI)
Palmitoyl-protein thioesterase 1 Infantile neuronal ceroid lipofuscinosis (CLN1)
Glycosylasparaginase Aspartylglycosaminuria
Adapted from J. Inher. Metab. Dis. 21 540-547 and J Gene Med 2004; 6: 481—506
Genetic lysosomal diseases have been known to occur spontaneously
in many mammalian species, but most of them occur among larger animais
that caimot 5e easiiy amenabie to genetic manipulation such as mice or rats.
Only two spontaneous mouse models of weil-delineated genetic lysosomal
diseases are known; 13-giucuronidase deficiency (mucopolysaccharidosis VII)
and the twitcher mutant (galactosylceramidase deficiency, Krabbe disease).
These models have been well characterized and closely duplicate the
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respective human defects in ail aspects (Ellinwood et ai, 2004) and so happens
with some of ffie induced mutants, such as acid sphingomyelinase deficiency,
t3-hexosamÏnidase f3-subunit (Sandhoff disease), galactosialidosis and total
sphingolipid activator deficiency. Conversely, a subgroup of those induced
mouse models shows minor deviations from human disease, including the
acid -galactosidase deficiency and f3-hexosaminidase a-subunit deficiency
(Tay-Sachs disease) among others.
Whfle mouse models have become necessary in the clarification of the
pathogenetic mechanism of disease and the exploration of therapeutic
approaches, species differences in the brain development and metabolic
pathways must 5e always remembered if the ultimate goal of the study is
application to human patients. When mouse models exhibit phenotypic
differences to those of human diseases, several factors are considered as the
underlying mecharilsm of ffiose differences. 0f primary importance is the lag
in developmental processes that occur at different lime intervals between
humans and mice, notabiy the absolute and relative time scales with respect
to the lifespan, and the variability in metabolic pathways (Suzuki et ai, 1998).
for example, neuronal proliferation and arborization in mice are initiated 7-8
days after birth, as opposed to prenatal completion in humans. At the same
time period, human newborn brains are already well into the active phase of
myelination in the telencephalon. An excellent example that illustrates the
effect of metabolic differences on the displayed phenotype is the Tay-Sachs
disease, which shows dramaticaily different clinical manifestations between
human and the genetically equivalent mouse disease. In humans, the
gangliosides containing a single sialic acid residue, known as GM1 and GM2,
are degraded almost exclusively by hydrolysis of the respective terminal
sugars, galactose and N-acetylgalactosamine. These reactions are catalyzed
by lysosomal J3-galactosidase and (3-hexosamiriidase-A, in the presence of
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their substrate specific cofactors saposin-B and GM2-activator protein,
respectively (Huang et ai, 1997). In contrast, in the mouse, GM1- and GM2-
gangliosides are readily degraded also by sialidase through sialic acid
removal to the respective derivatives, GAl and GA2, thus providing an
alternative route for their catabolism.
Diagnosis and strategies oftreatment
Theoretically, two approaches can lie envisaged in order to restrict the
amount of stored material inside the lysosome. First, we can provide the
missing enzyme either by direct administration, gene therapy or bone
marrow transplantation. Second, we can alleviate the amount of undigested
substrate by pharmacologically decreasing its rate of synthesis or by
restricting its ftow to the lysosome. In case of a lysosomal transporter defects,
equaliy valid would lie the possibiity to divert the transport of products or
by enhancing their export from the lysosome. for example, in cystinosis,
there is an intra-lysosomal accumulation of cysteine. Intralysosomal cysteine
levels can be decreased by oral administration of high doses of cysteamine, a
basic compound that reacts with the accumulated cysteine to form a mixed
disulfide resembling the structure of lysine, which is further transported
outside of the lysosome by the corresponding lysine amino acid transporter
(Winchester et ai, 2003).
The most widely used procedure for the diagnosis of LSDs is enzyme
assay and for most LSDs, this cari lie performed on leukocytes with fast
turnaround (Neufeld et ai, 2001). Cultured fibroliiasts are required in a few
LSDs. Cultured amniocytes or chorionic villus cells may be used for prenatai
diagnosis. Biochemicai determination of storage products is cumbersome, but
has some applications. for instance, demonstration of glucosaminoglycans
(GAG) in urine is a useful screening test for GAG storage. Storage of
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abnormal products can be detected in the ceils of the patient by light and
electron microscopy. In addition to neurons, gangliosides and ceroid
lipofuscin are stored in somatic celis and may be detected by nerve, muscle,
skin, conjunctival, and other biopsies. Tissue diagnosis (detection of specific
storage materials by electron microscopy) is sifil the standard for some NCLs
because biochemical assays of the affected proteins are not yet available. The
gene mutations of LSDs can be detected by DNA analysis. Mutation analysis
is used mainly for carrier detection and prognosis.
PROGRAMMED CELL DEATH (APOPTOSIS)
Celi death is a part of normal physiology for most metazoan species.
During development, redundant or unwanted cells are removed through
programmed cell death, making important contributions to morphogenesis,
organogenesis and other processes. However, excessive apoptosis, for
example, has been implicated in neurodegenerative diseases such as
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and
several hereditary diseases that are caused by extended polyglutamine
repeats (Yuan et al, 2000). Among the features of cells undergoing apoptosis,
as opposed to necrosis, are chromatin condensation, nuclear fragmentation,
plasma membrane blebbing, ceil shrinkage and ultimately shedding of
membrane-delimited ceil fragments known as apoptotic bodies (Arends and
Wyllie, 1991).
Apoptotic protease activation
The biochemical events that occur during apoptosis are the result of
hydrolysis of cellular proteins by a family of cysteine proteases called
caspases, which cleave specific target proteins at aspartic acid residues. 0f the
11 human caspases, 7 have defrnite (caspases 3, 6, 8, and 9) or probable
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(caspases 2, 7, and 10) roles in apoptosis, whereas the remainder is thought to
lie invoived in cytokine processing and the regulation of inflammation
(Honig et ai, 2000). Active caspases are teframeric enzymes consisting of two
large 17- to 37-kDa and two smail 10- to 12-kDa subunits. Caspases are
normally held in an inactive form by an integral hihibitory domain that
becomes the target of proteolysis upon their activation. Each caspase is
synthesized as a single-chain zymogen that contains an N-terminal
prodomain foliowed by one large and one smail subunit. Maturation of the
procaspases invoives cleavage at criticai aspartate residues, that is, at the
same type of bonds that caspases themselves cleave. This feature of caspase
activation provides the opportunity for autoactivation as well as the
possibility of caspase cascades. The advantage to the cell of this sfrategy is
that no protein sythesis is required to activate the apoptotic pathway given
that ail the components are already present.
Regutators of apoptosis
The Bd-2 family of proteins comprises both anti-apoptotic and pro
apoptotic members and has a pivotai role in controlling programmed celi
death by reguiating mitochondriai integrity and mitochondria-mediated
caspase activation (Adams et ai, 2001). There are at least 17 famiiy members,
which can be divided into three groups based on the presence or absence of
four conserved Bd-2 homology (BH) domains. The N-terminai BH4 domain is
present in ail anti-apoptotic family members, inciuding Bd-2, Bd-w, Bcl-xL,
Mci-1, A-1, Boo/Diva, and Nrf3. Pro-apoptotic family members, ail of which
lack the BH4 domain, fali into one of two categories. Either they are smaii
family members containing only the BH3 domain (e.g., Bid, Bad, Bik, Bim,
Blk, Bmf, Hrk, Bnip3, Nix, Noxa, and PUMA) or are iarger and resemble Bd-2
more closeiy but merely lack the BH4 domain (e.g., Bax, Bak, and Bok). The
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pro-apoptofic “BH3 orily” proteins present in higher eukaryotes (e.g., Bid,
Bim, Bmf) fransiocate from cytoplasmic sites to the outer surfaces of
mitochondria in response to apoptotic stimuli. The ratio between anti
apoptotic and pro-apoptotic Bd-2 members is a crucial factor that helps to
determine the susceptibiity of a ceil to a death signal (Hengartner, 2000).
In addition to Bd-2 family members, a famÏly of polypeptides called
IAP (irihibitor of apoptosis) proteins also regulates apoptotic processes
(Deveraux et ai, 1999; Salvesen et ai, 2002). Human members of this family
include clAPi, cIAP2, XIAP, NAIP and livin. Common structural features
include one or more baculovirus inhibitor repeat (BIR) motifs and RING
domains. The zinc finger-like BIR domains bind the surfaces of caspases,
allowing sequences between the BIRs to block the caspase active site. In this
manner, XTAP, clAPi, and cIAP2 are able to block caspase 8- and 9- initiated
events in vitro and to inhibit the activities of purified caspases 3, 7, and 9. The
RING domain acts as an ubiquitin ligase and presumably facifitates
proteasome-mediated degradation of whatever these IAP proteins bind
(Kaufmann et al. 2001).
Two Pathways of Caspase Activation
Apoptosis-signaling pathways can 5e categorized into three phases:
initiation and caspase activation, mitochondrial commitment and effector
events (Fig. 2, p.2l). According to current understanding, there are at least
two major pathways of apoptotic caspase activation (Hengartner, 2000). One,
calied ffie “death receptor” or “exfrrnsic” pathway, ufflizes caspase 8 and/or
10 as the initiator caspase in a protease cascade. The other, called the
“mitochondrial” or “infrinsic” pathway, invoives caspase 9. Though the
initiation and early spectrum of caspase activation differ between these two
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pathways, both these signal transduction pathways converge at the activation
of caspases 3 and 6, which are the two widely studied effector caspases.
APOPTOTIC SIGNAL
ccli stressors prescnce or loss of
extracellutar ligands
Bcl-2L Bax t
mitochonddal relcaseof subplasmalemmal associations ut
cytochrome e ami mitochondrial cytoplasmic receptor domains
pcrmeahility transition (nil’T) and adapb.r proteins
initial ettcctnr caspasrs (5, 9)
aggregation and activation
ettector caspases 3, 6, 7) activatîon
cleavage ofactin, polytAt)P—rihnse) polynierase
1CAD cleavage & endonuclease activation
+
FINAL APOPTOTIC PROCESSES:
DNA Fragmentation, Proteoivsis, Plasma membrane changes, Etc.
FIGURE 2 Molecular elements of the apoptofic cascade (Honig et ai, 2000)
The “extrinsic” or “death receptor” pathway begins with ligation of
specific celi surface receptors. In the case of fas, binding of its cognate ligand
(Fas ligand) resuits in an alteration of the so-called “death domain” in the
cytoplasmic tau of the receptor to permit binding of the death domain
containing adaptor molecule FADD. As a consequence of this binding, the
“death effector domain” of FADD acquires the ability to bind homologous
domains in procaspase 8, thereby drawing this zymogen to the site.
Molecular interactions within this assembly, which is called a DISC, resuit in
cleavage of procaspase 8 and release of mature caspase 8 to the cytosol, where
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it cleaves both procaspase 3 and the small “BH3 only” Bd-2 family member
Bid (Hacker, 2000). Depending on the ratio of these cleavages, apoptosis
might be friggered directly or might depend on activation of the
mitochondriai pathway (intrinsic pathway).
Induction of apoptosis by a variety of toxic insuits, including radiation
and chemotherapeutic agents, is accompanied by changes in mitochondriai
function. These stimuli cause several mitochondrial changes, inciuding
decreases of mitochondrial membrane potential and the release of
polypeptides that normaily reside in the mitochondrial inter-membrane
space. Among the polypeptides released is cytochrome c. Once in the
cytopiasm, this protein binds to a scaffoiding protein called apoptotic
protease-activating factor-1 (Apaf-1). In the presence of cytochrome c and
dATP, Apaf-1 undergoes a conformationai change that facilitates binding of a
protein interaction domain calied a caspase recruitment domain (CARD) on
Apaf-1 to a similar motif present in the prodomain of procaspase 9. The resuit
is the formation of a Mr -700,000 complex calied an apoptosome that has
enhanced abiity to cleave pro-caspases 3 and 7 to active enzymes (Dimmeler
et ai, 1999). These caspases then contribute to the characteristic apoptotic
phenotype. Another mechanism that friggers apoptosis in response to celi
stress operates through the transcription factor p53, which is a major player
in the events of ceil cycle controi mainly in response to DNA damage. DNA
repair mechanisms are activated, but so is transcription of the gene for
another bd-2 family protein cailed Bax. Like Bad, Bax ailows cytochrome c to
escape from mitochondria, so if the DNA is not repaired in time, BAX
concentrations increase, cytochrome c escapes, and apoptosis ensues.
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The Consequences of Caspase Activation
In the last stages of apoptosis, once caspase 3 has been activated,
biochemical changes that characterize the apoptotic phenotype begin to
occur. Ffrst, caspase 3 directly participates in endonuclease activation. The
nuclease caspase-activated deoxyribonuclease (CAD/DFF4O) is a consti
tutively expressed nuclear protein that is ordinarily complexed with its
inhibitor ICAD. Caspase 3-mediated cleavage of ICAD resuits in the
liberation of CAD, which begins to digest the chromatin (Hacker, 2000).
Because chromatin in the linker regions is more accessible than chromatin
wound around histones, the net resuit is a characteristic intemucleosomal
pallem of DNA degradation. This intemucleosomal degradation is
accompanied by chromatin condensation, another hallmark of apoptosis.
Caspase 3 also cleaves procaspase 6, liberating the active form of this enzyme.
Together, caspases 3 and 6 cleave structural proteins of the nucleus (lamins
and NuMA), facilitating nuclear fragmentation. In addition, these two
proteases (primarily caspase 3) cleave more than 200 other cellular subsfrates,
thereby inhibiting DNA repair and celi cycle progression, inactivating signal
transduction pathways that are critical for survival, and activating a series of
enzymes that are thought to participate in cellular disassembly.
Caspase-Independent Pathways
Even though caspases appear to 5e critical for cleavage of key
subsirates during apoptosis, other effector molecules might also contribute to
the apoptotic phenotype. For example, apoptosis-inducing factor (AIT) is an
oxidoreductase that is released from mitochondria into the cytosol during
apoptosis (Daugas et al., 2000). It subsequently localizes to nuclei, where it is
capable of generating large (>50 kb) DNA fragments and inducing chromatin
condensation by unknown mechanisms. It is also important to recognize that
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some caspase-independent ceil deaths appear to be necrotic, that is, to
involve ATP depletion and loss of membrane integrity. When caspases are
inhibited, the primary lesions induced by various treatments (e.g.,
microtubule disruption or DNA damage) and the cytochrome e release that
follows sifil occurs. These changes might 5e sufficiently disruptive to cellular
metabolism so that celis wii ultimately die even if they cannot activate
caspases.
Attempts have been made to order caspase-independent ceil death
according to the celiular organelles involved such as the mitochondria,
lysosomes and the endoplasmic-reticulum (Ferri et ai, 2001). Interestingly,
active participation of lysosomal proteases such as cathepsins B and D has
been observed in cell death induced by several stimuli, including oxidative
stress, TNF-Œ, bile salt-induced apoptosis and chemotherapeutic drugs
(Broker et ai, 2005). Indeed, cathepsin B has been shown to act as an effector
protease, dowristream of caspases in certain ceil types (Foghsgaard et ai,
2001), and is capable of executing ceil death independent of the apoptotic
machinery in WEHI-S fibrosarcoma and non-small celi lung cancer (NSCLC)
ceils (Broker et ai, 2005). Other reports have shown that lysosomal proteases
can promote celi death more indirectly by friggering mitochondrial
dysfunction and subsequent release of mitochondrial proteins probably
through Bld fransiocation after lysosomal disruption by lysosomofropic
agents (Cirman et ai, 2004). Finally, lysosomal proteases have been reported
to directly cleave and activate caspases, thereby confirming that lysosomal
permeabilization often is an early event in the apoptotic cascade (Ferri et ai,
2001).
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UBIQUITIN-PROTEASOMAL SYSTEM (UPS)
Protein degradation by the ubiquitin/proteasome system plays a
primordial role in a broad array of basic cellular processes such as the ceil
cycle, signal transduction and development. Considering these numerous
processes, it is flot surprising that the system has been implicated in the
pathogenesis of many diseases such as Parkinson’s disease, Alzheimer’s
disease, ischaemia reperfusion injury, aging in the central nervous system
and diabetes. Proteins modffied by multiubiquitin chains are the preferred
substrates for degradation by the 26S proteasome, a multicatalytic protease
complex. The proteasome ïs a massive complex consisting of more than 20
protein subunits and having a sedimentation coefficient of 26 (26S)
(Ciechanover et al., 2000). It has a cap and barrel structure, with the cap
(referred to as the 19$ component of the proteasome) being the part that
orients the ubiquitinated proteins in preparation for degradation by the 20$
barrel component, wMch contains the proteases. This multicatalytic protease
is characterized by three major activifies, that is the tryptic, chymotryptic and
peptidylglutamyl hydrolytic activifies.
Ubiquitination of proteins is a complex ATP-dependent process in
which ubiquitin is sequentially activated by ubiquitin-activating enzymes
(El), transferred to ubiquitin-conjugating enzymes (E2) and then ligated to
protein substrates by ubiquitin ligases (E3). Ubiquitin is joined to the
subsfrate through the formation of an isopeptide bond between the C
terminus of ubiquitin (G1y76) and the side-chain of a lysine residue of the
substrate. An addffional conjugation factor, named F4, was recently described
and is involved in polyubiquitin chain elongation of at least a subset of
subsfrates in conjunction with El, E2 and E3.
Although targeting proteins for destruction by the proteasome is the
best-characterized task of ubiquitin, other functions are being discovered at a
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rapid rate. Examples for such proteolysis-independent functions are
ubiquitin-dependent endocytosis, trarscriptional confrol and DNA repafr
(Varshavsky, 1997). Many of these are regulated by alternative types of
ubiquitin modification, such as monoubiquitylation (in which only one
ubiquitin moiety is added), or by a non-canonical multiubiquitin chain. The
proteasome also plays an essentiai role in maintaining celi homeostasis by
degrading many rate limiting enzymes and crifical regulatory proteins.
Deubiquitinating enzymes and UCH-L1
Deubiquitinating enzymes (DUB) are proteases that specifically
hydrolyse ester, thiol ester and amide bonds to the carboxyl group of glycine
residue 76 of ubiquitin (Wing, 2003). These enzymes, in anaiogy with the role
of phosphatases in reversibie phosphorylation, perform the reversible
ubiquitination of proteins and can have important regulatory functions. They
are involved in processing of ubiquitin gene products, in negativeiy
regulating the functions of ubiquitination, in regenerating free ubiquitin after
protein degradation by the proteasome or the lysosome and in salvaging
ubiquffin from possible infraceilular adduct formation (Wilkinson, 1997). Ail
eukaryotes contain DUBs encoded by at ieast two gene families, the ubiquitin
carboxyl-terminai hydrolase (UCH) and the ubiquitin-specific processing
protease (UBP) famiiies, which comprise in total more than 60 known
members. The products of the UCH family were named for their activity in
hydroiysing smail amides and esters at the C-terminus of ubiquitin and have
also been shown to remove peptides and smail proteins, whereas the UBPs
are responsible for ubiquitin proprotein and ubiquitin fusion protein
processing.
Three human UCH isozymes have been cioned and they exhibit
marked tissue specificity. For instance, UCH-L3 is an isoform specificaily
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expressed in hematopoetic ceils, wheres UCH-L1 is higffly expressed in
neurons (Doran et ai, 1983) and to ceils of the diffuse neuroendocrine system
and their tumors. Day and Thompson (1987) cloned UCH-L1 cDNA and the
deduced protein, which they called PGP9.5, contains 212 amino acids. Day et
al. (1990) determined that the UCH-L1 gene contains 9 exons and spans 10 kb.
The 5-prime region contains elements common to many genes and other
elements that are shared with the 5-prime regions of the genes encoding
neurofilament neuron-specific enolase (ENO2) and THY1 antigen. By
Northern blot analysis, Leroy et ai. (1998) detected a 1.3-kb transcript
expressed only in brain and further confirmed the gene structure.
Examination of specific brain regions revealed expression in ail areas tested,
particularly in the substantia nigra. Ubiquitin C-terminal hydrolase Li
represents i to 2% of total soluble brain proteins (Wilkinson et ai., 1989).
Its occurrence in Lewy bodies and its function in the proteasome
pathway made UCH-L1 a compelling candidate gene in Parkinson disease. In
a German family with Parkinson disease, Leroy et al. (1998) identified a
missense mutation in the UCH-L1 gene, i1e93 to met (193M), which caused a
partial ioss of the catalytic activity of this thioi protease. They suggested that
this could lead to aberrations in the proteolytic pathway and aggregation of
proteins. In other studies, Lincoin et al. (1999) sequenced the entire coding
region of the UCH-Li gene in 11 families with a paftern of Parkinson’s
disease consistent with autosomai dominant inheritance. Although they
found polymorphisms in noncoding regions, the only amino acid change was
S18Y. The S18Y allele was found in approximateiy 20% of chromosomes in a
Caucasian population, suggesting that it is unlikely to 5e pathogenic. Lincoin
et al. (1999) concluded that the 193M variant must be a rare cause of
Parkinson’s disease or a harmless substitution whose occurrence in the family
reflected chance. However, Liu et al. (2002) found that UCH-Li, especiaily
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variants linked to higher susceptibility to Parkinson disease, caused the
accumulation of aipha-synuclein in cultured ceils, an effect that could not 5e
explained by its recognized hydrolase activity. Therefore, UCH-L1 exhibited
an additional dimerization-dependent ubiquityl ligase activity. Interestingly,
the polymorphic variant of UCH-L1 associated with decreased risk for
Parkinson disease, serl8 to tyr (S18Y), had reduced ligase activity compared
with the wildtype enzyme, but it had comparable hydrolase activity. The
authors concluded that the ligase and hydrolase activifies of UCH-L1 may
play roles in proteasomal protein degradation, a process critical for neuronal
health. Osaka et al. (2003) recently demonstrated that monoubiquitin is
stabiized by its direct association to UCH-L1. This team investigated the
effect of a UCH-L1 loss of function on ubiquitin levels, as in the gad (gracile
axonal dystrophy) mouse, where neuronal monoubiquitin levels were
reduced compared to wild-type.
Animal mode!for UCH-L1 deficiency (GAD mouse)
The gracile axonal dysfrophy (gad) mouse is an autosomal recessive
mutant that shows sensory ataxia at an early age, followed by motor ataxia
later (Yamazaki et ai, 1988). Pathologically, the mutant is characterized by
‘dying-back’ type axonal degeneration and formation of spheroid bodies in
nerve terminals. Pathologic observations in the human have associated brain
aging and neurodegenerative diseases with progressive accumulation of
ubiquitinated protein conjugates. In gad mice, accumulation of amyloid
f3 protein and ubiquitin-posifive deposits occur retrogradely along the
sensory and motor nervous systems.
Suh et ai. (1995) showed that the gad mutation is located on mouse
chromosome 5. Later, Saigoh et al. (1999) found that the gad mutation is
caused by an in-frame deletion including exons 7 and 8 of the UCH-L1 gene,
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encoding the ubiquitin carboxy-termirial hydrolase selectively expressed in
the nervous system and testis. The gad allele encodes a truncated UCH-L1
protein lacking a segment of 42 amino acids containing a catalytic residue.
Since this protein is thought to stimulate protein degradation by generating
free monomeric ubiquitin, the gad mutation appears to affect protein
turnover. The findings showed ffiat altered function of the ubiquitin system
directly causes neurodegeneration and suggestes that the gad mouse
provides a useful model for investigating human neurodegenerative
disorders.
Kurffiara et al. (2000) showed that mice homozygous for a targeted
deletion of the related UCH-L3 gene are indistinguishable from wildtype. To
assess whether the two hydrolases have redundant function, Kurihara et al.
(2001) generated mice homozygous for both UCH-L1 (gad) and UCH-L3Q3-
7). The double homozygotes weighed 30% less than single homozygotes and
displayed an earlier onset of lethality, possibly due to dysphagia. Axonal
degeneraffon of the nucleus tractus solitarius and area postrema of the
medulla was noted in these mice. 11e double homozygotes also displayed a
more severe axonal degeneration of the gracile tract of the medulla and spinal
cord than had been observed in UCH-L1 (gad) single homozygotes. In
addition, degeneration of dorsal root ganglia celi bodies was detected in both
the double homozygotes and UCH-L3Q\3-7) single homozygotes. Given that
both UCH-L1 (gad) and UCH-L3Q\3-7) single homozygotes displayed distinct
degenerative defects that were exacerbated in the double homozygotes, the
authors concluded that UCH-L1 and UCH-L3 may have both separate and
overlapping functions in the maintenance of neurons of the gracile tract,
nucleus tractus solitarius, and area postrema.
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Rote of ubiquitination in apoptosis
The relation between ubiquitin and apoptosis was first suggested
when increases in ubiquitin expression were observed during programmed
ceil death in the intersegmental muscle of insects (Schwartz et ai, 1990) and
mature lymphocytes. This hypothesis was further reinforced by evidence
1irking proteasome inhibition to the activation of celi death in human
leukemic HL6O celis (Drexier, 1997). Today, it is widely accepted that
ubiquitin is critically involved in the regulation of molecules at every phase
of apoptosis. Important regulators of apoptosis, including the Bd-2 family of
proteins, the lAPs and regulators of the iriliibitor of nuclear factor-KB kinase
(IKK) have been identilied as new sulistrates of the ubiquination system. In
addition, the tumour suppressor p53 and other celi-cycle proteins that are
akeady known to be subsfrates of the proteasome have now been assigned
specific functions in the regulation of apoptosis. Moreover, lAPs, which are
pivotally involved in the negative regulation of pathways that induce death,
have themselves been shown to take part in the ubiquitylation of apoptotic
substrates.
Despite the amount of work correlating the variation in ubiquitin
levels (and ubiquitination paffem), proteasomal subunit composition and
proteasomal activity to apoptosis, proteasomal inhibition does not exhibit a
clear directional correlation. That is to say that the downsfream effects to
proteasomal inhibition, in terms of apoptosis, may be either positive or
negative in a ceil-type dependent maimer without negating the possibffity
that it changes the celi susceptibiity to apoptotic stimuli. These seemingly
contTadictory results might be due to the unspecific nature or concentrations
of the inhibitors that were used, or to differences between the celi types
(Orlowski et ai, 1999). An illustration of the above assertion is that most
stages of lymphocytes and most leukemic ceil mes become sensitized to
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apoptosis following proteasome inhibition, whilst primary thymocytes do not
in response to dexamethasone, y-irradiation, phorbol ester or etoposide
freatment (Lee et ai, 2003). As a general ruie, in most celi lis, proteasome
inhibitors frigger apoptosis.
As mentioned eariier, the JAP famiiy inhibits apoptosis primarily by
inactivating and degrading pro-apoptotic proteins and presents the only
known subset of apoptosis-signaiing molecuies that contain E3 iigase acffvity
(Deveraux et ai, 1999) by the presence of RING domains. The mechanism of
IAP-mediated inhibition of apoptosis predominantly lies in its interaction
with caspases such as casp 3, casp 7, casp 9, which resuits in their
ubiquitination and subsequent degradation by the UPS.
Ubiquitination of the Bd-2 proteins is known to target for degradation
both pro- or anti-apoptotic family members. Recent reports indicate that the
ubiquitin/proteasome system decisiveiy influences the deiicate balance
between these two fractions of the Bci-2 famiiy. Degradation of pro-apoptofic
members such as Bid, Bax and Bak has been reported to promote celi survival
and converseiy, apoptotic progression has been found to requfre poiy
ubiquitin-mediated Bd-2 degradation. Proteasomes have aiso been noted to
modulate apoptosis by affecting the iffe time of the ‘BH3-only’ members BH3-
interacting-domain death agonist (Bid) and Bd-2 interacting kiiler (Bik).
The p53 tumor suppressor protein is one of the best-known pro
apoptotic proteins acting at the transcriptionai levei and its induction occurs
foiiowing infrmnsic stressors, such as DNA damage, and ieads to a hait in celi
cycle progression and/or apoptosis activation. Foliowing activation by
various stresses, p53 downreguiates anti-apoptotic proteins, such as Bd-2 and
the transcription factor (3-catenin (Sadot et ai, 2001), and upregulates several
death-promoting moiecuies such as the adaptor protein Apaf-1, Bax, Noxa,
Puma, etc (Lee and Peter, 2003). The role of each of these proteins in p53-
31
mediated apoptosis seems to be ceil-type dependent. In addition, p53 might
also confribute to the induction of apoptosis through franscriptionally
independent activities (Ryan et al. 2001). The mechanisms that underlie these
functions remain poorly understood, but might point to a direct role for p53
at mitochondria and the relocalization of death receptors to the ceil surface.
For example, p53 was shown to directly interact with Bax protein leading to
its activation and to ffie subsequent permeabifization of the mitochondrial
membrane (Chipuk et ai, 2004). The ieveis of p53 protein are usually quite
low, as its rapid degradation prevents the accumulation of p53 in normal
proliferating ceils. The stabiity of p53 is highly regulated, primarily by its
abiity to bind the cellular proto-oncogene Mdm2, which functions as an
ubiquitin ligase for p53, mediating its ubiquitination and proteasome
degradation. The expression of Mdm2, in turn, is regulated by p53, producing
a feedback loop that tightly regulates p53 function.
Several stress-induced signaling pathways leading to ffie inhibition of
MDM2-mediated degradation of p53 have been identified. Kinases activated
by genotoxic damage, including ATM and ATR, Chkl, Chk2 as well as other
sfress-related kinases, have been shown to phosphorylate and thus stabffize
p53 (Abraham, 2001). Furthermore, the response to p53 phosphorylation on a
particular residue may depend on the specific stress signal initiating the
phosphorylation event, underscoring the complexity of p53 phosphorylation
and stabiization. Regulation of p53 nuclear localization also piays an
important role in confrolling p53 function and its abiity to fransactivate
responsive genes. The abffity of p53 to 5e exported from the nucleus is
certainly enhanced by Mdm2 ubiquitin ligase activity (Ryan et ai, 2001).
Unlike polyubïquitination, the functional consequences of monoubi
quitination are diverse and include receptor endocytosis, virus budding,
transcription, DNA repair and caspase recruitment during apoptosis.
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Concerning apoptosis, four proteins are targeted by monoubiquitination:
ifistone H2A, caspase-3, caspase-7 and DEDD. The role of monoubi
quitination of the above proteins in apoptosis remains speculative since this
field is stiil under development, but a cunent hypothesis is that a lattice
formation of ubiquitinated proteins forms and may act as a signaling
platform (Lee and Peter, 2003).
Involvernent of ZIPS in neurodegeneration
Genetic data from various species clearly hidicate the existence of a
link between proteasomal dysfunction and neuronal disorders. Moreover, an
increasing body of evidence supports a crucial role for the apoptotic system
in the manifestation of many of the neurodegenerative diseases, although our
knowledge about the mechauisms that are involved in these disorders is sifil
incomplete.
Neuronal death takes place within hours to days after a stroke, but
may occur over years in Alzheimer disease (AD). Mter a traumatic injury or
stroke, neurons die rapidly because of excitotoxicity (typically occurring
within 48 h) and apoptosis (typically occurring within 4-14 days) (Honig and
Rosenberg, 2000). There can also 5e extensive apoptosis of astrocytes and
oligodendrocytes during tifis period. In confrast, neuronal death in diseases
such as AD or Parkinson disease (PD) occurs over a period of years as a resuit
of necrosis induced by oxidative stress and the accumulation of protein
aggregates. The steady accumulation of protein aggregates in late-onset
neurodegenerative diseases presents an ongoing insuit to neurons that causes
steady, progressive injury and steady, progressive cell death. Conversely,
preventing the accumulation of toxic protein aggregates appears to 5e the
most effective sfrategy for inhibiting neurodegeneration in these progressive,
late-onset neurodegenerative diseases (Orr et al, 2000). The toxic aggregates
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cause ongoing injury, which differs from the lime deiimited celi death
stimulus typically associated with apoptosis. Late-onset neurodegenerative
diseases constitute a diverse array of diseases that are ail characterized by the
loss of specffic populations of neurons and the accumulation of parficular
types of inclusions in each disease (Alves-Rodrigues et ai, 1998). Table W
(p.34) lists aiso some of the major neurodegenerative illnesses, the nerve
populations that are affected in each ilness, and the proteins ffiat make up
the inclusions. In some cases, some of the general pathophysiologicai
mechanisms are known, but the specific factors that cause death of a selected
population of neurons is poorly understood. There is a growing consensus
that oxidative stress plays a key role in both aging and the pathophysiology
of most neurodegenerative diseases.
A key factor determining cellular vulnerabiity to oxidafive stress
appears to 5e protein oxidation and protein aggregation (Alves-Rodrigues et
ai, 1998). Many neurodegenerative diseases contain inclusions characteristic
of that disorder. Each inclusion contains a particular type of protein that is
present in an aggregated state, often as a fibrilar aggregate. For example,
mutations in two proteins, APP or presenilins, winch increase production of
rapidly aggregating amyloid-[3, cause familial AD. Expansions of
polyglutamine stretches cause proteins such as huntinglin and ScaI to
aggregate, winch causes Huntington’s disease and spinocerebellar ataxia,
respectively (Ross, 1995). Mutations in tau protein and Œ-synuclein increase
the tendency of each of these proteins to aggregate and cause frontotemporal
dementia of chromosome 17 and PD, respectively. Accumulating evidence
shows that these protein aggregates cause toxicity through a number of
different mechanisms.
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For many years, neuropathologists have noted that the inclusions that
form in a neuron are Mgffly ubiquitinated (Table W, p.34) and
immunostairing for ubiquitin represents one of the most sensitive methods of
detecting inclusions (Lennox et al., 1989). One reason why ubiqufflnated
inclusions accumulate is that the UPS is impaired in many neurodegenerafive
diseases. The significance of ubiquffination only recently became appreciated
with the discovery that one of the key disease-related genes, termed parkin, is
an E3 ubiquitin ligase (Kitada et ai, 1998). The UPS in affected regions of cases
of PD and AD shows a decrease in activity of between 30% and 40%
(McNaught et ai, 2001). The causes of this decrease, ffiough, are somewhat
contToversial. Although proteasomal activity generally increases in response
to oxidative stress, ffie latter combined with reduced ATP production
(associated with celi injury) might reduce UPS activity in neurodegenerative
disease (Conconi et ai, 1996).
The debate in this area centers on whether the protein aggregates
themselves inhibit the UPS. Most recently, many protein aggregates have
been shown to inhibit the proteasome, which is a process that causes acute
apoptosis in celis grown in culture (Bence et ai, 2001; Snyder et ai, 2003).
Similarly, large protein aggregates that accumulate in the endoplasmic
reticulum, termed aggresomes, inhibited the proteasome (Johnston et ai,
1998). Aggregates of huntingtin and the CFTR (cystic fibrosis transmembrane
conductance reguiator) both inhibit the UPS. However, whether UPS
inhibition accounts for the mechanism of ceil death associated with
—amyioid, a-synuclein and tau is iess clear. For instance, Œ-synuciein binds
the TBP1 protein of the proteasome, and overexpressing Œ-synuclein inhibits
the proteasome, but there is no evidence showing that aggregated c
synuclein inhibits the proteasome more than monomeric a-synuclein (Snyder
et ai, 2003).
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Together, the overail work in this field suggests that oxidative stress
does generally inhibit the UPS in many neurodegenerative diseases but that
the contribution of protein aggregates to inhibition of the UPS might vary
among different diseases. The concordance of these different unes of evidence
leads to the conclusion that protein aggregation is a process that is
fundamentally important to the progression of neurodegenerative disease,
and therefore investigating the pathophysiology of disease-related aggregates
could provide fundamental insights into the pathophysiology of neurode
generative disease.
INTRODUCTION
The genetically determined deficiency of lysosomal enzymes and
proteins, or of proteins involved in the lysosomal biogenesis resuits in
lysosomal storage disorders (LSD), which are characterized by the
accumulation of partially undegraded catabolic products in lysosomes
leading to their increased size and number. This severeiy affects celi turnover
causing malfunction of many tissues and organs, and leads to
hepatosplenomegaly, corneal clouding, skeletai deformation and central
nervous system degeneration. Aithough rapid progress has been achieved in
revealing the genetic basis of many lysosomai storage diseases, much less is
known about the mechanisms underlying the disruption of celi metabolic
and signailing pathways associated with these conditions.
Multiple studies have demonsfrated that the increased occurrence of
programmed ceil death (apoptosis) in many tissues and orgaiis of patients
affected with LSDs as well as in corresponding animal models resuits in the
elimination of entire classes of ceils (reviewed in Buccoliero et ai, 2002). For
exampie, high ievels of apoptosis were detected in neurones, microglia, and
Purkinje ceils of patients affected with Tay-Sachs disease, Gioboid celi
ieukodystrophy (Krabbe disease), Nieman-Pick disease type C, GM1-
gangliosidosis and Gaucher disease (Burek et ai, 2001; Erickson & Bernard,
2002; Finn LS et ai, 2000; Huang et ai, 1997; 1m et ai, 2001; Jatana et ai, 2002;
Jeyakumar et ai, 2003; Lozano et ai, 2001; Zhou et ai, 1998). In addition,
apoptosis of cartilage ceils (chondrocytes) was detected in mucopoly
saccharidosis (MPS) Type VI (Simonaro et ai, 2001) while apoptosis of muscle
celis ieading to ioss of cardiac muscle mass and cardiomyopathy was found
in Pompe disease (Hesselink et ai, 2003). Apoptosis was aiso observed in the
cultured fibroblasts and renal tubular epithelial ceils from patients affected
wfth cystinosis (Park et ai., 2002). In severai cases accumulated substrates of
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the deficient enzymes (such as psychosine in globoid celi leukodysfrophy, or
ceramide in farber disease) were directly shown to be cytotoxic and to induce
apoptosis, whereas apoptosis was considered to resuit from general
inflammation in the central nervous system in patients with GM2- and GM;
gangliosidoses (Jeyakumar et ai, 2003). Taken together these data suggest that
a high rate of apoptosis in the tissues affected in LSDs is a generai
phenomenon ffiat does not depend on the primary genetic defect but rather
originates from overfilling of the lysosomes with storage materiais.
To identify genes whose expression was aitered by ffie presence of
lysosomal storage products, our iaboratory previousiy used oligonucleotide
microarrays to compare mRNA transcript leveis in cultured skin fibroblasts
from normal individuais with those in fibroblasts obtained from patients
affected with sialic acid storage disease (SIASD) and sialidosis. Although
these conditions are caused by different primary genetic defects and resuit in
the accumulation of different storage products, they are ail characterized by
signiflcantly increased lysosome number and volume in many celi types
(Igdoura et ai, 1994; Renlund et ai, 1986). A total of 53 probe sets, representing
43 known genes and 6 ESTs were differentially expressed in each of the three
patient celi unes. Many of the differentiaily regulated franscripts were
consistent with previousiy described phenotypes of LSD ceils (Table V, p.4O).
For example, the suppression of numerous proteins and enzymes involved in
the formation of the extracellular mafrix (transglutaminase 2, different types
of collagen; tissue inhibitor of metalioproteinase 3; elastin; aggrecan 1;
versican) correlates with the reduced abffity of LSD fibroblasts to form elastic
fibers (Hinek et ai, 2000). On the other hand, the majority of differentiaiiy
regulated franscripts identffied in our microarray studies have not been
previously reported in association with LSDs (Table V, p.40). This latter
group includes ubiquitin C-terminal hydrolase Li (UCH-L1), a member of
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deubiquffinating enzymes family presumably involved in ubiquitin recyciing
to maintain pools of monomeric ubiquitin in the celi. Malfunction of the
ubiquitin pathway due to UCH-U deficiency has previously been associated
with neuronal degeneration in a small number of patients with autosomal
dominant Parkinson’s disease (PARK8) (Leroy et ai, 1998). As neuronai death
and dysfrophy is also a characteristic feature in LSDs, we wished to further
characterize the relationship between decreased UCH-L1 expression and
LSDs.
Our emerging hypothesis was that lysosomal storage might impair ceil
function and trigger apoptosis via the inhibition of the ubiquitin-mediated
protein degradation pathway. The main objectives of the current project, in a
perspective of providing general dues about the pathogenesis of LSDs, were:
1. To characterize the expression pattern of UCH-L1 in a group of
lysosomal storage disorders (in human fibroblasts and tissues of
LSD mouse models)
2. To study the overali invoivement of the ubiquitin-proteasome
degradation pathway in the ceiluiar pathogenesis of LSD and its
possible implication in the mechanisms of apoptosis.
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MATERIALS AND METHODS
Cet! culture
Human skin fibroblasts from patients affected with LSDs
(galactosialidosis (GM05076), GM1-gangliosidosis (GM05653, GM05335),
Morquio syndrome types A (GM00958) and B (GM01602, GM03251) sialidosis
(GMO1718A, FP2601), Gaucher disease types I and II (GM00852, GM00372),
and sialic acid storage disease (FP0421) as well as from normal controls
(FP0065, FP0075, fP0996, FP0221, FP0342) were obtained from the NIGMS
Human Genetic Mutant Celi Repository and from the Ste-Justine Hospital celi
repository. Celis were cultured in MEM supplemented with 10% fetal caif
serum. To induce lysosomal storage, ceils were freated for O-48 h with the
cysteine protease inhibitor E-64 (epoxysuccinyl-leucylamido-(4-
guanidino)butane, Sigma, Saint-Louis, MO) which was added directly to the
culture medium at a final concentration of 0.5 mM.
mRNA quanttfication by reat-time PCR
Total RNA was isolated from ceils using Trizol reagent (Invifrogen)
according to the manufacturer’s instructions. RNA quantity and quality was
analyzed specfrophotomefrically and by agarose-formaldehyde gel
electrophoresis. After the extraction of total RNA, first strand cDNA
synthesis was performed in presence of random primers using Superscipt II
reverse transcriptase (Invifrogen). Removal of RNA complementary to cDNA
was achieved by incubating the newly synthesized cDNA with 2 units of E.
cou RNAse H (Invitrogen) at 37°C for 20 min. PCR amplification was
performed on a SmartCycler (Cepheid) using the SYBR Green PCR kit
(Qiagen). The primer pairs, annealing temperatures, number of PCR cycles,
and RNA amounts are shown in (Table VI, p.42), which also shows the
42
predïcted sizes of the resulting PCR products. As posifive confrols for real
time PCR detection, we used mRNA coding for ribosomal subunit 18S
(Ambion) and mouse J3-actin.
Table VI PCR primers and conditions used to measure concentration of
UCH-L1 mRNA in cultured fibroblasts and mouse brain.
Gene Primers PCR conditions Product
length
Forward: 95°C 900 sec.
6GGCCAATGTCGGGTAGATGA 45 cycles of:
UCH-L1 Reverse: 94°C 15 sec. 100 bp
GAACTGGCGCCATGGTTCA546 60°C 30 sec.
72°C 30_sec.
Universal 1 $S Internai Standards primers 95°C 900 sec.
(Ambion, Austin, TX) 35 cycles of:
18$ rRNA 94°C 15 sec. 315 bp
°63 C 30 sec.
72°C 15_sec.
Forward: 95°C 900 sec.
. 937ACGTTGACATCCGTÀGACCT 45 cycles of:
13-actin Reverse: 94°C 15 sec. 100 bp(mouse)
GCAGTAATCTCCTTCTGCATCC’°36 60°C 30 sec.
72°C 30_sec.
Confocat immunofluorescence microscopy
Skin fibroblasts of normal confrols and of patients affected with LSDs
were freated for 1 h with 75 nM LysoTracker Red DND-99 dye (Molecular
Probes, Eugene, OR), washed twice with ice-cold PBS and fixed with 3.8%
paraformaldehyde in PBS for 30 min. Celis were permeabilized by 0.5%
Triton X-100, blocked with 10% goat serum in PBS for 1 h, stained with
monoclonal anti-UCH-L1 antibodies, or monoclonal anti-ubiquitin antibodïes
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both from Novocastra (Newcastle, UK) and counterstained with oregon
green 488-conjugated anti-mouse IgG antibodies (Molecular Probes, Eugene,
OR). Alternatively ceils were double stained with FffC-labeled monoclonal
anti-UCH-L1 antibodies, or monoclonal anti-ubiquitin antibodies and Texas
Red-labeled monoclonal antibodies against LAMP-2 (Washington
Biotechnology Inc., l3althnore). Also, immunocyotchemical staining for
GAPDH (Ambion) and FLAG tag (Stratagene) was performed using
corresponding mouse monoclonal antibodies. Slides were studied on a Zeiss
LSM510 inverted confocal microscope (Cari Zeiss Inc., Thornwood).
Apoptosis or programmed celi death was detected immuno
cytochemically using the in situ ceil death detection kit or TUNEL method
from Roche. The basis of such method relies upon the labeling of DNA strand
breaks resulting from DNA fragmentation, by terminal deoxynucleotidyl
fransferase enzyme, which catalyzes polymerization of labeled nucleotides to
free 3’-OH DNA ends in a template-independent manner. The TUNEL
reaction preferentially labels DNA strand breaks generated during apoptosis
(emission on the green channel) as opposed to necrosis. After fixation in 3%
paraformaidehyde for 45 min. fibroblasts cuitured under different conditions
were permeabffized for 30 min in 0.1% Triton X-100 (in 0.1 % sodium citrate)
and incubated for 1 h at 37°C upon addition of the TUNEL reaction mixture.
After blocking with 10 % fBS for 30 min, addffional immunocytochemical
double or triple stafriing was performed if necessary.
Programmed ceil death was also detected using the sulforhodamine
multi-caspase ac%vity kit from Biomol, which detects active caspase enzymes
(casp. 1-9) in living ceils as the SR-VAD-FMK reagent covalently attaches a
fluorescent label to the reactive cysteine residue of the active site exposed
upon proteolytic cleavage of the zymogens. Confluent fibroblast ceils
cultured under given conditions (with or without E-64 freatment, fransfected
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or not with siRNA for GAPDH and UCH-L1) were incubated for 1 h at 37°C f
under 5% COQ) with the SR-VAD-FMK reagent (Biomol), washed, fixed in
3.8 % paraformaldehyde in PBS for 45 min and permeabiized by 0.5% Triton
X-100 for 30 min. The ceils were either directly observed under the
fluorescence microscope or additionally stained for UCH-L1 and/or DAPI.
Euzymatic assays
Ubiquitin hydrolase activity was assayed using AMC-ubiquitin
substrate (BostonBiochem, Cambridge, MA) as described more in detail by
Liu et al. (2002). The pellet from harvested cultured ceils was resuspended in
buffer containing 50 mM Tris-HC1 (pH 7.6), 0.5 mM EDTA, 5 mM DTT (UCH
buffer ) and, following brief sonication on ice, the rates of substrate
hydrolysis were determined from the initial linear portion of the kinetic
curves (10 mi. The same procedure was followed for mouse brain tissues,
which were homogenized in UCH buffer and the lipids removed by filtration
in a three-layered cheesecloth.
Caspase-3 activity was measured after determining the initial linear
part of the kinefic curves using a fluorogenic caspase-3 substrate II Ac
DEVD-AMC and the caspase-3 inhibitor I Ac-DEVD-CHO both from
Calbiochem (Darmstadt, Germany). After freatment of normal fibroblasts
with 0.5 mM E-64 for given time intervals or skin fibroblasts taken from LSD
patients, the celi pellets were harvested and lysed in buffer containing 0.32 M
of sucrose, 10 mM of Tris-HC1 (pH 8.0 ), 5 mM EDTA and 1% of TritonX-100
for 30 min on ïce. Mter centrifugation at 10,000 x g for 10 min at 4°C, the
supernatant or celi lysate was used for assaying the caspase-3 activity.
The lysosomal enzyme 13-hexosamiiiidase was assayed using the
corresponding fluorogenic 4-mefflylumbefliferyl (Muf)-glycoside derivative as
substrate (Pshezhetsky and Potier, 1996). The reaction mixture contahuing 50
45
jtl of the cellular homogenate, 40 pi of 0.1 M sodium acetate buffer (pH 4.6)
and 10 jil of Muf-NANA substrate in the same buffer was incubated at 37 oc
for 30 min. The reaction was terminated by the addition of 1.90 ml of 0.4 M
glycine buffer (pH 10.5) and the concentration of Muf was assayed
fluorometrically.
Western btothng
Cultured ceils from LSD patients, confrols and 0.5 mM F64 (Sigma,
Saint-Louis, MO) freated ceils were harvested and homogenized in Laemmli
buffer, which was heated for 3 min at 85°c. Protein concentration was
determined specfrophotomefrically using ffie reducing agent and detergent
compatible Biorad protein assay kit. cellular proteins were resolved by 5-15%
PAGE pre-cast gels from hwifrogen and elecfrofrarisferred on nifroceflulose
membrane. Ponceau’s staiiiing of ffie nifrocellulose membrane and alternative
staining for cytoplasmic -actin using mouse monoclonal f3-actin (Abcam)
antibodies were used as internai confrols to normalize for ffie amount of
protein. In ffie case of ubiquitin inimunoblots, the membranes, after being
sandwitched between whatmann ifiters, were autoclaved in TBS for 30 min at
1100 c to increase ffie sensffivity of ffie assay as described by Swerdlow et al.
(1986) and stained wiffi rabbit/mouse (for UCH-L1, fLAG and GAPDH
inimunoblots) polyclonal anti-ubiquitin antibodies (Sigma). Subsequently,
anti-mouse or anti-rabbit peroxidase-conjugated secondary antibodies were
used for ffie detection with BM chemiluniinescence blotting subsfrate kit from
Roche (Penzberg, Germany). The same procedure was performed also for
mouse brain homogenates and cultured cells, but using this time antibodies
directed against hurnan UcH-L1 (mouse monoclonal, Novocastra), GAPDH
(mouse monoclonal, Ambion) and FLAG (mouse monoclonal anti-fLAG-M2,
Stratagene), except for the membrane autoclaving.
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Proteasornat activity assays
Proteosomal activity was assayed as described by Rodgers et al (2003),
where fractionation of ffie ceil lysate by ulfrafilfration in conjunction wiffi gel
ififration was used to obtaïn a proteasome rich fraction almost devoid of
contaminating protease activiffes ffiat derive from low molecular weight
intracellular proteases.
Mouse whole brain was trimmed into small pieces on dry ice and
homogenized in a buffer containing 50 mM Tris-HC1 (pH 7.8), 20 mM KC1,
0.5 mM magnesium acetate, 1 mM DTT (Buffer A) using a glass tube
homogenizer. The homogenate was ffltered through a three-layered
cheesecloth to remove lipids and the filtrate was cenfrifuged at 12,000xg for
10 min at 4°C. Conversely, human skin fibroblasts were harvested from 150cm2
flasks and lysed by three freeze-ffiaw cycles in 1 ml water containing 1 mM
DTT and the lysate was centrifuged at 14000 x g for 30 min at 4°C to remove
any insoluble material.
The supernatant was diluted 20-fold in fresffly prepared buffer A
containing 10% (v/v) glycerol and 2 mM ATP, concenfrated to original
volume using a polyethersulfone ultrafiifration membrane with a cut-off of
500 kDa (Millipore, Bedford, MA) and subjected to FPLC gel-filtration on a
Superose 6 I-W 10/30 FPLC column (Pharmacia Biotech, Castie Hill, NSW,
Australia) equilibrated by ffie same buffer. The addition of 10% glycerol and
ATP to the buffer during the membrane separation was required to maintain
proteasome activity.
1-ml fractions were collected and assayed for tryptic and chymotryptic
activities using N-Suc-LLVY-AMC (Biomol, Plymouth Meeting, PA) and Boc
LRR-AMC (Bachem, Bubendorf, Switzerland) and in the presence or absence
of the proteasome specific inhibitor lactacystin (Calbiochem) as described by
Rodgers and Dean (2003).
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UCH-Ll overexpression studies and apoptosis detection
pCMV-Sport6 vector containing full-length human UCH-Li (PGP 9.5)
cDNA was purchased from Invifrogen. b obtain a plasmid coding for UCH
Li-fLAG fusion protein, the cDNA was amplified using modffied primers
aiming the removal of stop codon (AAGCTTATGCAGCTCAAGCCGATGG
and CTCGAGGTAGGCTGCCTTGCAGAGAGC) and containing flanking
Hindili and XhoI sites. following gel purffication of the -‘670 base-pairs PCR
product (Wizard PCR Preps DNA Purification System, Promega), it was
cloned into pCR2.1 TOPO vector according to the manufacturers indications
(TOPO TA Cloning kit, Invifrogen) and then subloned as a HindIII/XhoI
fragment into pCMV-Tag 4a vector by preserving a continuous open reading
frame between PGP 9.5 and the FLAG tag. Ihe consfruct was entirely
sequenced and expressed in COS-7 celis to ensure that fLAG-tagged protein
retains catalyffc activity.
Normal skin fibroblasts were elecfroporated with 20 jig of pCMV
UCH-L1-fLAG vector in MEM containing 1.25% (v/v) DMSO using Gene
Pulser II apparatus (Bio-Rad) set at 290 V and 950 tf (0.55 kV/cm). 24 hours
after transfection the ceils growing on glass siides were freated with 0.5 mM
E-64 for an additional 24 h, fixed, stained with monoclonal anti-FLAG
peptide antibodies/Texas Red-conjugated anti-mouse IgG antibodies
(Molecular Probes, Eugene, OR) and counter-stained for apoptosÏs using
TUNEL (Fluorescein in Situ Celi Death Detection) kit from Roche.
Altematively, prior to immunocytochemical studies celis were treated for 1 h
with LysoTracker Red prior and counterstained with DAPI (Molecular
Probes).
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CAChapter AQuantification of UCH-L1 protein in brain extracts by
tandem mass spectrometry
DAChapter AMass specfrometry (MS) has the abiity to identffy and to
quantffy thousands of proteins from complex samples with great sensitivity,
speed and accuracy (Aebersold and Maim, 2003) (Fig. 3, p.49). In order to
quantffy and compare the UCH-L1 protein levels, total brain tissues of
HEXB+/+ and HEXB-/- mice were dissolved in Laemmli buffer and analysed
by SDS-PAGE. Gels were either stained with Coomassie Blue or transferred
to nifrocellulose membrane for western blotting with anti-UCH-L1
anfibodies. Gel pieces contairing UCH-L1-immunoreactive band were
excised from Coomassie-stained gels and subjected to fryptic digestion and
peptide extraction as described below. Samples were analyzed on ion-frap
LC-MS/MS instrument (Nanoflow proteomic solution, Agitent). Spectra were
interpreted and quantffied using a Spectrum Miil software (Agilent) interface.
The gel was stained in Coomassie blue/20% methanol/0.5% acetate
for 1 h and then destained in 30% methanol unifi the background was nearly
clear. The gel slices of interest, as indicated by the position of the UCH-L1
immunoreactive bands, were cut in a sterile environment and were washed
for 1 h in 500 j.tl of 100 mM ammonium bicarbonate prior to the reduction of
the suifflydryl groups with 2.8 mM DTT solution in lOOmM ammonium
bicarbonate. Aikylation of the proteins was performed by adding 10 il of
100 mM iodoacetamide to the gel plug and standing at room temperature for
30 min in the dark unifi the gel became partially dehydrated. The supernatant
was then removed and the gel slices were washed in 500 d of 50% aceto
nifrile/100 mM ammonium bicarbonate with shaking for 1 hr. Next, the
dehydration step was performed by adding 50 tL of acetonitrile to the gel
pieces for 15 min and drying to dust-like appearance in the rotary evaporator.
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FIGURE 3 Genene mass spec&omeby (MS)-based proteomics experiment.
By definition, a mass specfrometer consists of an ion source, a mass analyser ffiat measures
ffie mass-to-charge ratio (rn/z) of ffie ionized analytes, and a detector ffiat registers ffie
number of ions at each m/z value. Mass specfromeftic measurements are carried out in the
gas phase on ionized analytes. Electrospray ionization (ESI) and mafrix-assisted laser
desorption/ïonization (MALDI) are ffie two techniques most commonly used to volatize and
ionize the proteins or peptides for mass specfromefric arialysis. The typical proteomics
experiment consists of five stages. In stage 1, the proteins to be analysed are isolated from
ceil lysate or tissues by biochemical fracifonation (eg. SDS PAGE) or affinity selection.
Proteins are degraded enzymatically to peptides in stage 2, usually by frypsin, leading to
peptides with C-terminally protonated amino acids. Tri stage 3, the peptides are separated by
one or more steps of HPLC and eluted into an ESI ion source where they are nebulized in
small, higMy charged droplets. Mter evaporation, muffiply protonated peptides enter the
mass specfrometer and, in stage 4, a mass spectrum of the peptides eluting at this time point
is taken. The computer generates a prioritized list of these peptides for additional
fragmentation and a series of tandem mass spectrometric or MS/MS’ experiments ensues
(stage 5). The MS and MS/MS spectra are typically acquired for about one second each and
stored for matching against protein sequence databases. The outcome of the experiment is
the identity of the peptides and therefore the proteins making up the purffied protein
population. (Adapted from Aebersold and Mann, 2003)
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The gel pieces were swollen or rehydrated with 10 j.il of 25 mM ammonium
bicarbonate contairiing Promega modffied trypsin (sequencing grade) in a
subsfrate to enzyme ratio of 10:1. The digestion reaction was kept at 37°C
overnight and the resulting peptides were extracted twice into the organic
phase with 50 tl of 60% acetonitrile/0.1% TFA for 20 min and then dried in a
rotary evaporator. The dried digest extract was redissolved in 20 tl of
aqueous solvent containing 0.1% of TfA acid for subsequent ESI LC-MS/MS.
UCH-L1 small interfering RNA gene sitencing in human skin fibrobtasts
RNA interference can induce potent gene silencing through
degradaffon of complementary mRNA (Fig. 4, p.52). Synthetic siRNAs
fransfected into mammalian celis can resuit in a transient decrease in
expression of the target gene for 3-5 days. Si1encer pre-designed siRNA
targeting exons 4 and 5 of the human UCH-L1 gene (Table VII, p.5O) were
obtained from Ambion (Austin, IX).
TABLE VII siRNA pnmers used to downregulate UCH-L1 in cultured fibroblasts.
s•• Target sequence iW 0ZC Targeted exon(s)
Sense:
5’-GGAAAAAGCAGAUUGAAGAtt-3 21 6827.2 33 14teti1[ï3(5)lN_10418LEXl44 A1lt 14238
14138
Antisense
—
5-UCUUCAAUCUGCUUUUUCCt5-3 21 6468.2 38 h)
Sense:
Taqtttd hsi(s): IN 104181: Etit 4
5-GGGACAAGAAGUOJAGUCCUtt-3 21 6733.2 43 - sR10Se 14227
14227 — 4151
Antisense: (1111 )
5-AGGACUAACUUCUUGUCCCU-3’ 21 6567.2 43
Sense:
5-GGAUGGAUCAGUUCUGAAAtt-3’ 21 6734.2 38 T1t;1s45 14331
14311
— Nt4041
Antisense: 1111 bps)
21 6536.2 435-UUUCAGAACUGAUCCAUCtc-3
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Cultared skin fibroblasts were fransfected with siRNA using the
Lipofectamine Plus transfection kit (Invitrogen). GAPDH siRNA (Ambion)
was used as a positive confrol for the optimization of transfection conditions.
Prior to the experiments with normal control fibroblasts, siRNA efficacy was
verified using human skin fibroblasts immortalized by transduction with
retroviral vectors expressing the type 16 human papilloma virus F7 gene and
the catalytic component of human telomerase (kindly provided by E.
Shoubridge, Monfreal Neurological Institute). The ceils were harvested 24
and 48 hours after fransfection with 3 UCH-L1 siRNAs and UCH-L1 protein
level was assessed by Western biot and immunocytochemistry as described
above. Total RNA purified from a separate pool of transfected cells was used
to measure UCH-L1 mENA level by real-time PCR. The most effective UCH
Li siRNA (ID# 14311) was selected to perform the suppression experiments
in normal skin fibroblasts.
48 h after transfection, normal skin fibroblasts treated with UCH-L1
siENA (final concentration in culture medium was 50 nM) and mock
fransfected fibroblasts were fixed and permeabilized as described above. 24 h
after transfection, a subset of UCH-L1-transfected and mock-transfected cells
was also treated for additional 24 h by 0.5 mM E-64. Ail celis were stained
using a TUNEL kit as described above and counterstained for UCH-L1
protein as described above. Programmed cell death was also detected using
the sulforhodamine multi-caspase activity kit from Biomol, containing a SR
VAD-FMK subsfrate of caspases 1-9. For this, 4$ h after fransfection, live celis
were incubated for 1 h at 37°C with SR-VAD-FMX reagent as recommended
by manufacturer, washed, fixed and counterstained for UCH-L1 protein.
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FIGURE 4 Mechanism of RNA mterference (RNAi).
RNM is a phenomenon in which ffie introduction of double-sfranded RNA (dsRNA) into a
diverse range of organisms and ceil types (step 1) causes degradaffon of the complementary
mRNA. On entry into ceils, dsRNA is cleaved by Dicer ribonuclease into 21- to 23-nt siRNAs
(step 2). SiRNAs containing overhangs of 2 to 3 nucleotides at boffi 3’ ends of the sense
(identical to target mRNA sequence) and antisense sfrands can also be fransfected directly to
the ceil wiffi possibility of achieving fransient gene-specific silencing. To overcome the
fransient inhibitory effects of fransfected RNA molecule synthesis in vitro, expression
plasmids, mostly based on RNA polymerase ifi promoters, have been designed to achieve
long-term or stable inhibition of ffie target genes. The siRNAs subsequently assemble with
protein components into an RNA-induced silencing complex (RISC), which is able to unwind
the siRNA and target it to bind the complementary sequence on the host mRNA franscript
(step 3). The bound mRNA is cleaved (step 4) and sequence specific degradation of mRNA
(step 5) resuits in gene silendng (reviewed in Dilin, 2003).
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Detection ofpro- and anti-apoptotic proteins in UCH-L1
siRNA-treated ceits
Fibroblasts transfected with UCH-L1 siRNA for 12, 24 and 48 h and
mock-fransfected confrols were fractionated as described (Gobeil et al., 2003).
Briefly, ceils were suspended in lysis buffer (10 mM Tris-HC1, 10 mM NaC1, 3
MgC12, 30 mM sucrose, pH 7.4) and homogenized with a glass homogenizer
(300 sfrokes); lysate was cenfrifuged at 700 g for 10 min at 4°C to remove
nuclei and debrïs, and the supernatant re-centrifuged at 10,000 g for 15 min
to obtain mitochondria-contahilng pellet. The supernatant was cenfrffuged
again at 120,000 g 1 h to obtain the S100 cytosolic fraction. The nuclear
fraction was additionally purffled by washing with the lysis buffer
containing 0.120 % NP-40 and cenfrffuged at 800 g for 10 min. Protein
extraction was performed as previously described (Senrilaub et al., 2003)
using 50 mM Tris-HC1 (pH 7.4), 1 % NP-40, 0.25% sodium-deoxycholate
(Sigma), 150 mM NaC1, 1 mM EDTA, 2 mM Na3VO4 (Sigma), lmM NaF and
protease inhibitor cocktail (Roche), for 30 min incubation at 4° C.
20 or 30 ig of protein from the total lysate, mitochondrial, nuclear or
cytosol fractions were analyzed by SDS-PAGE. Proteins were fransferred to
PVDF membranes and probed with antibodies against Bax (clone 6A7 of
Pharmingen and B-9 of Santa Cruz for the cleavage of Bax to generate pi8
fragment), Bd-2 (Pharmingen), p53 (clone Pab 240, NeoMarkers), cytochrome
C (Pharmingen) and f3-actin (Abcam). Intensities of the immuno-reactive
bands were measured using Image Pro Plus software (version 4.1.00) from
Media Cybemetics.
Statisticat Methods
Statistical analysïs was performed using the two-sample Wilcoxon test.
RESULTS AND DISCUSSION
UCH-L1 AND LYSOSOMAL STORAGE
Oligonucleotide microarrays performed on normal skin fibroblasts and
skin fibroblasts obtained from patients with LSDs such as sialic acid storage
disease and sialidosis revealed a number of franscripts that were
differentially regulated and that were common to both LSDs, independently
of the kind of storage material accumulated in the lysosomes. Since one of the
most easily observable features of celis with lysosomal storage is the
overwhelming increase in the number of lysosomes and thefr size, we
performed an immunocytochemical staining for the lysosomal integral
membrane protein LAMP-2 in SIASD and sialidosis human skin fibroblasts.
In confluent cultured skin fibroblasts, a 3-5-fold increase in lysosomal storage
bodies was detected by immunohistochemical stafriing with anti-LAMP-2
antibodies (Fig. 5, p.55) as well as by staining with a lysosome-specffic dye,
LysoTracker Red (flot shown).
Since the UCH-L1 gene was downregulated in SIASD and sialidosis
disorders in conjunction with an increase in the lysosomal storage bodies, we
proceeded in verifying if tins deubiquffinating enzyme was also
downregulated in other lysosomal disorders with different primary genetic
defects. Cultured human skin fibroblasts were first used for tins purpose in
addition to brain tissues from mouse models of human Sandhoff disease with
defective hexosaminidase-B gene.
Reduced UCH-L1 mRNA tevets infibrobtastsfrom LSD patients and
Sandhoff mouse brains
In order to confirm the suppression of UCH-L1 expression detected by
microarray experiments and to determine if UCH-L1 expression ïs altered in
55
ceil Unes obtained from patients aftected wiffi offier LSDs, we analyzed ffie
level of UCH-L1 mRNA by real-time PCR in cultured skin fibroblasts from 5
different healthy controls and from 11 patients affected wiffi ffie following
LSDs: SIASD (1 une), sialidosis (2 Unes), galactosialidosis (1 Une), GM1-
gangliosidosis (2 Unes), Morquio syndrome type A (1 Une) and B (2 Unes), and
Gaucher disease (types I and II, one Une each).
Ail ceil Unes were passed an equal number of times and had similar growffi
rates. These experiments (Fig. 6, p.56) demonstrated ffiat ffie level of UCH-L1
mENA in ffie affected ceil Unes was significantly reduced (mean 23.5 %,
median 23 % of normal) compared to an internai control (18S mRNA). Some
ceil limes, alffiough they have ffie same primary genetic defect, showed
significant variabffity in ffie UCH-L1 mRNA levels between patients. For
FIGURE 5 Lysosomal storage bodies in the ceils of patients affected with sialidosis and
sialic acid storage dïsease (SIASD). Skin fibroblasts from normal confrols (A, D) and from
patients affected wiffi sialidosis (B, E) and SIASD (C, F) were cultured to confluency, fixed,
stained wiffi a mouse monoclonal anti-human LAMP-2 anfibody, and counterstained wiffi
oregon green 488-conjugated secondary antibodies. Ceil nuclei were visualized with DAPI.
Slides were studied on a Zeiss LSM51O inverted confocal microscope. Magriffication 600x.
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exampie, sialidosis patient 1 (SL1) had aimost twice higher UCH-L1 mRNA
levels than sialidosis patient 2 (SL2) and similariy for Morquio syndrome
type A (MA) patients. This finding shouid not 5e at ail surprising since there
is an evident genetic variability between individuais and that LSDs are
heterogeneous in nature with varying residual enzyme activities (Grabowski
and Hopkin, 2003).
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FIGURE 6 Suppression of UCH-L1 in cultured fibroblasts obtained from LSD patients.
UCH-L1 mRNA levels in control fibroblasts (Cont, n=5) and in ceils from patients affected
wiffi sialic acid storage disease (SIASD), sialidosis (SL 1 and SL 2), galactosialidosis (GS),
GM1-gangliosidosis (GM1 1 and GM1 2), Morquio syndrome type A (MA) and B (MB 1 and
MB 2) and Gaucher disease types I (GI) and II (Gil). The UCH-L1 mRNA was quantffied by
RT-PCR as described. UCH-L1 mRNA level is presented as a fraction of ffiat in normal
confrol celis (Cont). Values represent means ± S.D. of friplicate experiments.
The aiteration in UCH-L1 transcripts observed in cultured celis of
patients was also confirmed in total brain extracts obtained from mice in
which the iysosomal hexosaminidase B (HEXB) gene was inactivated by
homoiogous recombination (Phaneuf et ai, 1996). This constitutes a weli
studied modei of Sandhoff disease that replicates most of the aspects of its
human counterpart. Consequentiy, homozygous HEXB nuli mice (HEXB-/-)
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represent a reliable animal model of human Sandhoff dïsease and develop
lysosomal storage bodies as well as a high rate of apoptosis in fleurons,
microglia and Purkinje ceils (Huang et ai, 1997). We found that UCH-L1
mENA was reduced to about 30% in homozygous mutant mice (HEXB-/-) as
compared to ffieir wild type siblings (HEXB+/+) (Fig. 9, p.59). The mENA
level in heterozygous siblings (FTEXB+/-) ffiat were asymptomatic for LSD
was not statis%cally different from transcript levels seen in ffiefr wild-type
sibllngs.
SASD
GM1I
MB 2
FIGURE 7 Inimunohistochemical detection of UCH-L1 in control ceils (C) and ceils
obtamed from LSD patients. Plates of confluent ceils were flxed, stained wiffi a mouse
monoclonal anti-UCH-L1 aiffibody, and counterstained wiffi oregon green 488-conjugated
secondary antibodies. Slides were studied on a Zeiss LSM51O inverted confocal microscope.
Magiiificafion 400x.
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Reduced ubiquitin hydrolase activity and UCH-L1 protein levels in
fibrobtasts ofL$D patients
The results of these expression studies were confirmed by several
biochemical experiments. First, we performed immunohistochemical staining
of UCH-L1 in normal fibroblasts and in fibroblasts from LSD patients. Anti
UCH-L1 ùmnunoftuorescence in control skin fibroblasts showed a diffuse
paftem consistent with the previously described infracellular localization of
the enzyme, which is mainly cytosolic (Fig. 7, p.57). The ceils of patients
showed similar localization of UCH-L1, but the intensity of staining was
significantiy reduced in ail unes reflecting lower protein levels (fig. 7, p.57).
Second, we assayed ubiquitin hydrolase activity in the homogenates
and found that it was signfficantly reduced in the celis of patients as
compared to confrol fibroblasts (Fig. 8, p.58). Although the level of ubiquitin
hydrolase activity somewhat correlates with the level of UCH-L1 mRNA in
the patient celis, the ubiquitin hydrolase on average is reduced onlyto about
50% of normal control, suggesting human fibroblasts contain both UCH-L1
(Olerud et al., 1998) as well as other de-ubiquitinating enzymes.
1.00 FIGURE 8 Ubiquitin hydrolase
acflvity in confrol ceils and celis of
075 i Z[ LSD patients.Plates of confluent ceils were
harvested and ubiquitin hydrolase
I activity in ffie total ceil homogenate
was measured wiffi AMC-ubiquitin as
described by Liu et al (2002). Specific
0.25 ubiquitin hydrolase activity is
presented as a fraction of ffiat in
normal control cells (Cont). Values
0.00
Cont SISD G1 G2 -
- 2
represent means ± S.D. of friplicate
experiments.
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Reduced UCH-U protein levels in Sandhoff mouse brains
In order to determine wheffier ffie alteration in UCH-L1 expression
levels observed in cultured ceils of LSD patients might also accompany ffie
neurodegeneration seen in LSDs, we assayed ubiquitin hydrolase activity
and UCH-Lf protein in total brain exfracts of Sandhoff mouse brains. As we
showed ffiat UCH-L1 mRNA levels were diminished in HEXB-/- mice in
comparison wiffi their wild-type siblings HEXB+/+, we subsequently found
that UCH-L1 was also aftected at the protein level. Ubiquitin hydrolase
activity was reduced approxhnately 2-fold in the HEXB-/- mice when
compared to wild-type animais (Fig. 9, p.59). Alffiough ffie absolute values of
ubiquitin hydrolase were significantly higher in mouse brains ffian ffiose in
human fibroblast homogenates, ffie degree of reduction was consistent
between ffie two models.
UCH-L1 actïvity (n=15) UCH-L1 mRNA (n25)
FIGURE 9 Comparison of UCH-L1 cDNA and protem levels in total brains of Sandhoff
mouse model fHEXB-/-, HEXB+/- and HEXB+/+ siblings). * p<O.001 as compared to wild
type HEXB+/+ mice.
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FIGURE 10 Western blots for UCH-L1 in Sandhoff mouse brains. Western of brain
lysates of HEXB-/- and HEXB+/+ siblings of Sandhoff mouse model with monoclonal anti
UCH-L1 antibodies. 20 ig of total protein was loaded per lane. Ponceau staining and f3-actin
were both used as loading controls (not shown). The position of UCH-L1 protein is shown
on the right side of the blot.
Western biots also showed reduced levels of UCH-L1 protein in 5 of $
homogenates tested (Fig. 10, p.60), but since resuits signfficantly varied
between the different HEXB-/- mice, we decided to use a mass-specfrometry
based approach to quantify UCH-L1 protein directly in pooled whole brain
exfracts. Pooled exfracts of HEXB-/- and pooled exfracts of HEXB+/+ mice
were separated by SDS-PAGE. Gel pieces containing the UCH-L1 protein
band as detected by western blot in exfracts obtained from HEXB-/- and
HEXB+/ + mice were excised from gels, freated with trypsin and analyzed by
tandem mass spectrometry coupled to liquid chromatography (LC-MS/MS).
Based on the differences in MS spectra intensity and in the number of
unique UCH-L1 peptides detected in each sample (Fig. 11, p.6l), we
concluded that UCH-L1 protein levels were reduced approximately 2-fold in
brain exfracts of HEXB-/- animais when compared to wild-type animais.
Recent data indicated that in the brains of patients affected with Alzheimer’s
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disease and Parkinson’s disease, UCH-L1 undergoes post-translational
modffications such as carbonylation, methionine oxidation and cysteine
oxidation (Choi et ai, 2004) which significantly alter its activity. Our
experiments also detected ffie presence of ffie UCH-L1 isoforms wiffi 3
oxidized methionine residues, but ffie ratio between modified and non
modffied protein was similar for HEXB+/+ and HEXB-/- animais.
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fIGURE 11 Identification and quantification of UCU-Li protem in bram lysates of
(HEXB-/- and HEXB+/+ siblings) Sandhoff mouse model by tandem mass spectrometry.
Upper panel - tandem mass spectra of ffie triply-protonated precursor ion with m/z of
662.13 obtained from nanoLC-MS analysis of a 25-kDa UCH-L1 cross-reacfive hand.
Lower panel - UCH-L1 peptides identified by Spectrum MDI software, thefr scores, relative
aburidance in brain homogenates of HEXB-/- and HEXB+/+ mice and location iii ffie UCH
Li sequence. Analysis of relative 3-ac6n spectral intensities and spildng wiffi known
amounts of recombinant UCH-L1-FLAG protein were used as loading confrols.
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E-64-induced lysosoma! storage resutts in reduced expression of UCH-L1
In order to determine whether reduced levels of UCH-L1 mRNA and
protein resulted directly from the accumulation of the storage materiais in
lysosomes, we induced this condition in normal celis by treating them with
the cysteine protease inhibitor E-64 (epoxysuccinyl-ieucylamido-(4-
guarildino)butane). This compound enters celis by pinocytosis and inhibits
lysosomai protein degradation, causfrtg a significant increase in the number
and volume of lysosomes as well as the formation of multivesicular dense
bodies (Doherty et ai, 1989; Laszio et ai, 1990), thus mimicking to a great
degree the conditions of lysosomal storage.
In our experiments, 16-h incubation of normal confrol fibroblasts in the
medium containing 0.5 mM of E-64 was sufficient enough to significantly
cause an increase in the lysosome number and size as visualized by
immunohistochemical stairiing with anti-LAMP-2 antibodies (Fig. 12A, p.63).
These findings are almost identical to the LAMP-2 immunocytochemical
staining pattems performed on fibroblasts derived from patients with LSDs
such as SIASD, SL (Fig. 5, p.55), GS, GM1, MA, MB, GI and Gli (not shown).
Interestingly, these same organelles were also heavily stained with anti
ubiquitin antibodies as assessed by a strong colocalization (more than —80%)
of ubiquitin with Lysotracker dye, showing the accumulation of
ubiquitinated proteins in the lysosomes (Fig. 12B, p.63). Parallely, we
observed a diminished ubiquitin hydrolase activity of the order of —30 % in
the ceil lysates of the same normal confrol fibloblasts after being treated with
E-64 for 24 h (Fig 13, p.65). The UCH-L1 mRNA levels were equally
depressed after a 24 h E-64 freatment, but the decrease was much more
pronounced, almost half of the initial UCH-L1 transcript levels.
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FIGURE 12 Ubiquitinated lysosomal storage bodies in cultured skin fibroblasts treated
with E-64.
A) Lysosomal storage bodies in unfreated normal fibroblasts (Confrol) or normal fibroblasts
freated with 0.5 mlvi E-64 for 16 h (E-64 16h) or 24 h (E-64 24h). The ceils were fixed, stained
wiffi a mouse monoclonal anti-human LAIvW-2 antibody, and counterstained wiffi oregon
green 488-conjugated secondary antibodies. Ceil nuclei were visualized wiffi DAPI.
B) Immunohistochemical localization of ubiqutinated protefris in E-64-freated ceils.
Following incubation wiffi 0.5 mM E-64 for 24 h, celis were probed wiffi LysoTracker Red,
fixed, stained wiffi mouse monoclonal anif-ubiquitin antibodies, and counter-stained wiffi
oregon green 488-conjugated secondary antibodies. Panels show ubiquitin-related green
immuno-fluorescence (Ubiqutin), LysoTracker-related red fluorescence (LysoTracker) and
merged images. Magrffication 600x (panel A) or l000x (panel B).
Ubiquifin LysoTracker Merger
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UBIQUITIN-PROTEASOME PATHWAY IN LYSOSOMAL STORAGE
As it was demonsfrated in our experiments, the UCH-L1 franscripts,
protein and activity were decreased in fibroblasts with different LSDs and in
brains of Sandhoff mice. Since UCH-L1 is a predominant deubiquitinating
enzyme important for regenerating the ubiquitin monomer, it was
hypothesized to have an important regulatory role on the activity of the
proteasome. Therefore, a deficiency of UCH-L1 enzyme secondary to
lysosomal storage would resuit in impairment of deubiquitination processes
and decrease in the recycling of free monomeric ubiquffin, possibly impacting
the overali ubiquitin-dependent proteasomal activity. The idea of the
presence of ubiquitinated protein aggregates observed earlier in fibroblasts
treated with E-64 supported the aforementioned hypothesis (Fig. 12B, p.63),
as an hnpairment of the proteasomal activity would lead to additional protein
aggregate formation. The chymofryptic activity of the proteasome is most
often used to measure the proteasomal activity in celis and tissues, however it
has been shown that the three activities of the proteasome can 5e separately
regulated and a single substrate may not accurately reftect the total
proteasomal activity (Rodgers et al. 2003). In our case, proteasome substrates
for the chymotryptic and tryptic activities, which were previously shown to
display the greatest specfficity for their respective activities, were employed
to evaluate the overail state of the proteasome.
Decreased proteasornat activity in hurnanfibrobtasts with tysosomal
storage
Chymofryptic and fryptic activifies measured in the 26S and 20S
proteosomal fractions were both found to 5e significantly reduced in the ceils
of LSD patients (mean55% of confrol and SD± 12%) and in the E-64-freated
confrol ceils (mean 30% of confrol and SD± 3%) (Fig. 13B, p.65).
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FIGURE 13 Decrease of proteosomal activity in cultured skin fibroblasts from LSD
patients.
A) Gel-filtration of ffie exfracts of normal control skin fibrobïasts and of celis from SIASD
patients on FPLC Superose 6 column. Chymotryptic and tryptic proteolytic activities in
fractions 10-12 corresponding to ffie expected elution volume of 26S and 20S proteosomes are
significantly reduced. Positions of ffie elution of ffie Mr standards: ffiyroglobulin (669 kDa),
aldolase (158 kDa) and ribonuclease A (13.7 kDa) are shown by anows.
3) Proteosomal activity in normal confrol ceils (C), in the ceils from patients affected with
Morquio syndrome type B (MB), SIASO (SIASD), sialidosis (SL), GM1-gangliosidosis (GM1)
and in confrol ceils treated for 24 h with 0.5 mM cysteine protease inhibitor E-64 (E-64). Celi
exfracts were analyzed by gel-filtration as described. Combined chymofryptic and tryptic
activity in pooled fractions 10-12 is presented as a fraction of that in normal control ceils
(n=2). Values represent means ± S.D. of triplicate experiments.
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The proteosomal activity, however, was flot affected in the celis freated with
0.5 mM E-64 for 2 h (i.e. before the beginning of apoptosis) or when 1 mM E-
64 was added directly to the ceil homogenates, indicating that the inhibition
of the proteosomal activity was not caused by the unspecific action of E-64 on
the proteasome itself or the proteasomal subsfrates in use. In support of the
latter resuits are studies by Rodgers et al. (2003), where the 26S and 20S
proteasome-rich gel-filtration fractions were only inhibited by less than 5%
when 0.2 mM E-64 was directly added during the proteasome activity assays.
The lower molecular weight gel-filtration fractions 15-20, in addition to
remaining completely unaffected by lactacystin as opposed to the protesome
rich fractions 10-12 (‘-80 % inhibition), showed no significant difference in the
fryptic and chymotryptic activities between the confrols and the celis with
lysosomal storage (Fig. 13A, p.65).
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FIGURE 14 Decrease of proteasomal activity in brain tissues of Sandhoff mice.
Gel-filtration of pooled brain extracts of HEXB-/- and HEXB+/ + siblings of Sandhoff mice
on FPLC Superose 6 column. Chymofryptic proteolyfic activity is signfficantly reduced in
fractions 10-12 corresponding to ffie expected elution volume of 26S and 205 proteosomes.
Positions of the elution of ffie Mi standards: ffiyroglobulin (669 kDa), aldolase (158 kDa) and
ribonuclease A (13.7 kDa) are shown by arrows.
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Impaired proteasomat activity in Sandhoff mouse brains
The same frend was observed conceming the fryptic and chymotryptic
proteasomal activities measured in total brain homogenates of Sandhoff
HEXB-/- mice (fig. 14, p.66). The proteasomal-rich fractions 10-12 of HEXB
/- mice demonsfrated a marked decrease (almost 4 tintes iess) in both the
tryptic and chymotryptic activities when compared with wiid-type, strongly
suggesting that there is an impairment of the proteasome-mediated protein
degradation, hinting for its invoivement in the pathology of Sandhoff
neurodegeneration.
Lysosomat storage induces formation of ubiquitin protein aggregates and
reduced tevel offree ubiquitin
Since UCH-L1 is the major cellular ubiquitin hydrolase, we
hypothesized that its suppression as a consequence of lysosomai storage
should result in the accumulation of ubiquitinated protein conjugates in
lysosomal dense bodies as well as in decreased intraceliular levels of free
ubiquitin. These changes would in turn 5e expected to impair the
proteasomal ubiquitin-dependent protein degradation pathway, causing
further ceil deregulation and apoptosis. Previous studies have demonsfrated
that 20 to 30% of small and motor neurons of patients affected with Tay-Sachs
disease, Niemann-Pick disease, and Hunter disease showed anti-ubiquitin
immunoreactivity in confrast to the celis of normal confrols (Zhan et ai, 1992).
The celis of animal models of MPS VII (Heuer et al, 2002), Niemann-Pick
disease (Higashi et al, 1993) and prosaposin deficiency (Oya et ai, 1998) also
contained ubiquitinated protein aggregates. In our studies, 11 fibroblast mes
from patients affected with different LSDs had lysosomal dense bodies that
contained ubiquitinated protein aggregates. In addition, humunofluorescent
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microscopy wiffi a mouse monoclonal ariti-ubiquitin antibody revealed ffiat
ail ffie ceils from LSD patients showed a predominantly perinuclear punctate
staining pattem consistent wiffi mainly lysosomal localization of
ubiquitinated proteins (Fig. 15, p.68). Colocalization of ubiquitinated
aggregates wiffi lysosomal markers LAIvIP-2 and LysoTracker Red confirmed
that ffie lysosomal dense bodies were heavily ubiquitinated. Western blots of
total ceil homogenates showed ffiat ffie majority of cellular ubiquitin in LSD
patient ceils is associated wiffi high-molecular weight protein aggregates: in
contrast, il-te amount of free monomeric ubiquitin is sigriificantly reduced
(Fig. 16, p.69).
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FIGURE 15 Detection of ubiqmnated proteins in ceils with lysosomal storage.
Immunohistochemical localization of ubiqutinated proteins in confrol fibroblasts (C) and in
ceils of patients affected wiffi SIASD (SIASD), sialidosis (SL 1), galactosilalidosis (GS),
Morquio syndrome type A (MA) and B (MB 1) and Gaucher disease type II (CII). Ceils were
stairied with a mouse monoclonal anti-ubiquitin anffbody, and counterstained wiffi oregon
green 488-conjugated secondary antibodies.
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FIGURE 16 Ubiquifin western blot of fibroblasts of LSD patients.
Western blots of lysates of confrol ceils (Cl and C2) and ceils obtained from patients affected
with Morquio syndrome type A (MA) and B (MB1 and MB2), GM1-gangliosidosis (GM1),
sialidosis (SL), SIASD ($IASD) and Gaucher disease type II (Gil) wiffi anti-ubiquitin
antibodies. Each lane contains 40 ‘g of total protein. Immunobloffing was performed wiffi
anti-ubiquitin rabbit polyclonal antibodies. The position of ubi-qutinated protein aggregates
(Ub-Agr), ubiquitinated histone H2a (Ub-H2A) and free udiquitin (Ub) are shown on the
right side of blot.
APOPTOSIS AND LYSOSOMAL STORAGE
To further examine the relationship between lysosomal storage, UCH
Li inhibition and the induction of programmed ceil death, we treated normal
fibroblasts with E-64 for 6-48 h. Parallel plates of ceils were used to prepare
RNA for real-time PCR studies as well as to measure the UCH-L1 hydrolytic
ac%vity and the activities of lysosomal f3-N-acetyl hexosaminidase and
caspase 3 (Fig. 17, p.70). Real-time PCR studies showed signfficantly
decreased UCH-L1 franscript levels following 6 h incubation with E-64,
wMch correlated with the formation of lysosomal storage vacuoles (increase
of lysosomal f3-N-acetyl hexosaminidase activity). This increase in lysosomal
storage bodies upon E-64 freatment for 16h and 24h was as well observed by
lysosomal LAMP-2 immunocytochemical staining (Fig. 12A, p.63). A decrease
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FIGURE 17 Development of lysosomal storage, UCH-L1 deficiency and apoptosis in
culftred skin fibroblasts fteated with E-64. Cultured skin fibroblasts from normal confrols
were incubated wiffi or wiffiout 0.5 mM E-64. The ceils were harvested at ffie indicated Urne
intervals an! assayed for UCH-L1 mRNA level by RT-PCR (UCH-L1 mRNA), ubiquitin
hydrolase activity (Ub hydrolase), lysosomal j3-hexosaminidase acffvity (HEX) and caspase-3
acfivity (CASP 3) as described. Values represent means ± S.D. of friplicate experirnents.
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of UCH-L1 activity lagged 6 hours after the decline of its mRNA (Fig. 17,
p.70). Alter treatment of the ceils with E-64 for 24h, immunofluorescent
microscopy showed decreased levels of UCH-L1 protein (Fig. 18A, p.72).
After 46-h freatment of ceils with E-64, the UCH-L1 mRNA level increased;
however, by this time the majority of celis had developed apoptosis as
demonsfrated by increased caspase 3 activity (Fig. 17, p.7O), condensed nuclei
(Fig. 18B, p.72) and DNA-fragmentation (Fig. 1$C, p.72). This particular
series of experiments demonstrates that, in the early stages of lysosomal
storage, there is an accompanying decrease in UCH-L1 transcript levels,
followed thereafter by a depression of UCH-L1 protein and activity, ending
by an activation of caspase-3 and downsfream events of apoptosis (DNA
fragmentation and condensation).
Fibrobtasts with tysosomat storage disptay higher apoptosis rates
We observed celis with condensed nuclei (data not shown) as well as
TUNEL-positive celis in ail studied fibroblast lines from LSD patients (Fig. 19,
p.73). The number of apoptotic celis was variable, ranging from —5 to —95%
(nuclei condensation assay) and from —58 to —100% celis (TUNEL positive
celis). In confrast, control Unes cultured under the same experimental
conditions did not undergo apoptosis, showing that fibroblasts of LSD
patients undergo apoptosis at Mgh rate. Caspase 3 activity was detected in ail
LSD patient celi Unes but not in confroi ceils. Jndeed, these findings closely
resemble what was previously found when normal fibroblasts with E-64-
induced lysosomai storage and UCH-L1 dowriregulation had undergone
apoptosis (Fig. 17, p.70).
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FIGURE 18 E-64-treated fibroblats show decreased UCH-L1 protein and mcreased
apoptosis.
A) Immunohistochemical localization of UCH-L1 in control celis arid cefis freated with E-64
for 48 h. The ceils were stained wiffi a mouse monoclonal anti-UCH-L1 antibody, and
counterstained with oregon green 488-conjugated secondary antibodies.
B) Epifluorescent microscopy of DAPI-stained confrol celis and ffiose freated wiffi E-64 for 48
h. Arrowheads show condensed nuclei in apoptofic ceils.
C) Epifluorescent miaoscopy of TUNEL-stained confrol cefis and those freated with E-64 for
48 h. Slides were studied on ffie Nickon Ecipse E6000 direct epifluorescence microscope.
Magnification 400x.
Control E-64 48h
73
FIGURE 19 Development of apoptosis in cultured skin fibroblasts from LSD patients.
Normal confrol ceils (C) and ffie cefis of patients affected wiffi SLASD (SIASD), sialidosis (SL
1; SL 2), galactosilalidosis (GS), GM1-gangliosidosis (GM1 1), Morqulo syndrome type A
(MA) arid Gaucher disease type II (Gli) were stained for DNA fragmentation using a TUNEL
fluorescence kit. Slides were studied on the Nikon Ecipse F6000 direct epifluorescence
microscope. Magnification 400x.
Overexpression of UCH-L1 in fibrobtasts with lysosornal storage rescues
themfrorn apoptosis
b establish ffie causal relationship between decreased UCH-L1
activity and apoptosis, we studied E-64-induced apoptosis in normal skin
fibroblasts transfected with an expression vector coding for UCHL-1
containing a FLAC tag on ffie C-terminus (pCMV-UCHL-1-FLAG). lndeed, if
a UCH-L1 deficiency secondary to lysosomal storage was driving ffiese ceils
to programmed celi deaffi, the supplementation of functional UCH-L1 would
have the abffity to partially rescue ffiem. Separate experiments demonstrated
that COS 7 ceils transfected with pCIvW-UCHL-1 -FLAC expressed
catalytically active UCH-L1. 24 hours after fransfection wiffi eiffier pCMV
UCHL-1-FLAG or wiffi pCIvW-Tag 4a (mock), ffie fibroblasts were treated
with E-64 for an additional 24 hours, ffien fixed, stained wiffi anti-FLAC
peptide antibodies and assayed for apoptosis using a TUNEL kit. As shown
on fig. 20 (p.75), FLAC-positive ceils overexpressing UCH-Lf demonstrated a
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significantly reduced rate of apoptosis under our experimental conditions.
About 40% of confrol ceils (E-64-treated fibroblasts) were TUNEL positive,
whereas, only -7% of FLAG-positive celis showed TUNEL staining (Fig. 20,
p. 75). These resuits sfrongly support mir hypothesis that a deficiency in
UCH-L1 enzyme confributes to the increased apoptosis observed in celis with
lysosomal storage.
Suppression of UCH-Ll in normal fibroblasts induces caspase-mediated
apoptosis
Although we demonsfrate that the overexpression of UCH-L1 in ceils
with lysosomal storage prevents ceils from undergoing apoptosis, we cannot
prove that UCH-L1 deficiency can dfrectly cause apoptosis. In fact, as was
previously reviewed, lysosomal storage disorders encompass a series of
complex extralysosomal events, including the possibility that accumulated
storage material like ceramide in Farber disease, may dfrectly cause
apoptosis, although this particular finding was recently invalidated (Ségui et
al.). Thus, we transiently suppressed the expression of UCH-L1 in normal
human skin fibroblasts (without lysosomal storage) by siRNA-mediated gene
silencing, to discem the effects of UCH-L1 deficiency from those of lysosomal
storage products in apoptosis.
When we used siRNA to inhibit the expression of UCH-L1 in normal
confrol fibroblasts, we observed an important increase of apoptosis both in
the presence and in the absence of E-64. Our preliminary experiments
performed on immortalized fibroblasts showed that UCH-L1 siRNA 14311
completely inhibited synthesis of UCH-L1 protein in about 70% of ceils (Fig.
21A, p.77). On average, the UCH-L1 mENA level measured by RT-PCR was
reduced more then 7-fold (Fig. 21C, p.77). Pronounced reduction of UCH-L1
protein was also detected by the Western blot (Fig. 21B, p.77).
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FIGURE 20 Suppression of E-64-ïnduced apoptosis in cultured skin fibroblasts.
Normal control fibroblasts (Cont) and fibroblasts fransfected wiffi pCvW-UCH-L1-FLAG
plasmid (UCRL) or wiffi pCMV-Tag 4a plasmid (Mock) were incubated in ffie presence of 0.5
mM E-64 for 24 h. Then ffie ceils were fixed, and stained for the expression of UCH-L1-FLAG
fusion protefrt wiffi anti-FLAC peptide antibodies, and for DNA fragmentation using TUNEL
assay. Nuclei were stained with DAPI. A) Epifluorescent miaoscopy of randomly selected
representatives of pCvW-UCH-L1-FLAG-fransfected ceils freated with E-64 for 24 h. Pseudo
colors show DAPI staining (blue) TUNEL staining (green) and anti-FLAC staining (red).
Arrowheads show apoptotic TUNEL-positive ceils. Slides were studied using a Nikon
Edipse E6000 direct epifluorescence microscope. Magnification 400x. B) A cumulative
number of apoptotic deaths per 100 celis was counted based on TUNEL stairiing using
epifluorescent microscopy. For pCMV-UCH-L1-FLAG-ftasfected ceils apoptotic deaths were
counted separately for FLAC-negative (F-) and FLAC-positive ceils (F+). Values represent
means ± S.D. of triplicate experiments; from 200 to 300 celis were counted for each condition
for each experiment. * p<O.00l as compared to nonfransfected ceils, mock-fransfected ceils
or FLAG-negative ceils.
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When normal control fibroblasts were freated with a similar
concentration of UCH-L1 siRNA 14311 for 48 hours, the fraction of TUNEL
positive celis increased from 3-5% to -6O% (Fig. 22A, p.78). In the presence of
E-64, the fraction of TUNEL-positive ceils increased from 24% (mock
transfected celis) to 53% (siRNA-fransfected celis) (Fig. 22C, p.78), showing
that a further depression of UCH-L1 from the one caused by lysosomal
storage (E-64 induction) results in greater apoptosis (addititive effect). Similar
resuits were obtained after staining the ceils with a sulforhodamine multi
caspase activity kit, winch detects active caspase enzymes 1-9 in live celis.
Only 1-5% of mock-transfected ceils showed positive staining in the absence
of E-64, while 25% showed positive staining in the presence of E-64 (Fig. 22B,
p.78). for siRNA-fransfected celis, the fraction of caspase-positive ceils in the
absence of E-64 was 54% and in its presence 53% (Fig. 22C, p.78).
Interestingly, double staining of the celis with pancaspase substrate and with
anti-UCH-L1 antibodies or with anti-UCH-L1 antibodies and TUNEL kit
showed that apoptosis was triggered exclusively in the celis depleted of
UCH-L1 protein, suggesting that inhibition of UCH-L1 expression alone was
sufficient to cause the celi death in cultured skin fibroblasts (Fig. 22B,C).
Special attention should be drawn to the fact that, aside the statistical
differences or the negligible errors associated in the counting of apoptotic
ceils, both percentages of caspase activation and DNA fragmentation
(TUNEL) are identical upon siRNA freatment, suggesting that they are
related to the same event of apoptosis at the single-celi level. Due to technical
limitations in combùiing TUNEL and multi-caspase activity assays, the latter
assertion could not be fully verffied. However, it can stii be safely concluded
that the UCH-L1 siRNA-induced apoptosis implicates caspase activation.
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FIGURE 21 Inhibition of UCH-L1 expression in cultured human skin fibroblasts by
siRNA. Immortalized human skin fibroblasts were frarisfected wiffi UCH-L1 siRNA as
fridicated. 24 and/or 48 hours after fransfecifon ffie ceils were harvested arid UCH-L1
protein level was assessed by immunocytochemistry (A) and Western blot (B) as described
in Materials and Methods. From a separate pool of fransfected ceils, total RNA was purified
and used to measure UCH-L1 mRNA level by real-time PCR (C) Resuits shown represent at
least 3 independent experiments perfonned in triplicates (n=9). * p<O.001 as compared to
mock-fransfected ceils.
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FIGURE 22 Induction of apoptosis by siRNA-induced inhibition of UCH-L1 expression.
Fibroblasts fransfected with UCH-L1 siRNA (siRNA) and mock-transfected ceils (Mock)
were incubated in ffie absence and presence of 0.5 mM E-64 for 24 h. Then the ceils were
flxed, and stained for apoptosis using TUNEL kit or sulforhodamine muffi-caspase activity
kit. A cumulative number of apoptotic deaths per 100 ceils was counted based on TUNEL or
muffi-caspase acfivity staining using epifluorescent microscopy (A). Values represent means
± SD. of ftiplicate experiments. Between 450 and 800 ceils were counted for each condition
in each experiment. In a separate experiment ceils fransfected wiffi UCHL-1 siRNA were
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stained for TUNEL (B) or multi-caspase (C) ac%vity and counterstained for UCH-L1 protein
as described above. Pseudo-colors show multi-caspase activity staining (red), TUNEL
stahiing (green), DAPI staining (blue) and anti-UCH-L1 staining (red in B and green in C).
Apoptotic proteins bax, bd-2 and p53 are increased in UCH-L1 suppressed
fibrobtasts
In order to address the molecular mechanism by which a UCH-L1
deficiency triggers specific apoptotic pathways, we measured the level of
pro- and anti-apoptofic proteins in ceils treated with UCH-L1 siRNA 14311
for 12, 24 and 48 hours. After harvesting, nuclear, mitochondrial and
cytosolic fractions were prepared by differential centrifugation. The
subceiiuiar fractions and the total homogenates were anaiyzed by western
blots using antibodies directed against several known pro- and anti
apoptotic gene products. The expression of pro-apoptotic proteins Bax and
p53 was sigriificantly increased between 12 h and 48 h after treatment of the
ceils with siRNA (Fig. 23, p.81). Note that Bax was increased both in the ceil
lysate and the mitochondrial fractions, indicating in fact that bax fransiocates
somehow to the mitochondria. The same ceils showed a 2-fold increase of the
cytosolic cytochrome C level, consistent with its translocation from the
mitochondria to the cytopiasm through Bax-induced pore in the
mitochondrial membrane. The concentration of pro-survival protein Bd-2
was also slightiy increased in siRNA-treated celis, but this did not stop them
from undergoing apoptosis (Fig. 22A, p.78).
Numerous studies have shown that Bax as well as other apoptotic
proteins such as Bd-2 and p53, are targetted for degradation by the
proteasome (Lee et ai, 2003). In addition, the observed increase in nuclear p53
protein levels in the above experiments can possibly further upregulate the
pro-apoptotic protein Bax by its franscriptionai activity (Sadot et ai, 2001). In
celis where there is a transient UCH-L1 deficiency by siRNA freatment, it is
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probable that the ubiquitin-dependent proteasomal degradation was
negafively affected, with resulting increases in the stabiization of apoptotic
proteins and ceil cycle regulators, but this remains purely speculative until
further experiments are performed. In GAD mice with defective UCH-L1
however, ubiquitinated protein inclusions were observed (Saigoh et ai, 1999)
denoting a decrease in proteasomal activity. Meanwhile, it is less probable
that infralysosomal ubiquitinated storage bodies would be observed in UCH
Li siRNA-treated normal fibroblasts since there is seemingly no inhibition of
lysosomal degradation.
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FIGURE 23 Expression of pro- and anti-apoptotic proteins in cultured skin fibroblasts
treated with UCH-L1 siRNA.
Cultured human khi fibroblasts were fransfected wiffi UCH-L1 siRNA (siRNAjatmc
transfected celis (Mock). At ffie time periods indicated on ffie figure, celis were harvested and
fractionated on nuclear, mitochondrial and cytosolic fractions by differential centrifugation.
20 ig of total protein from cytosol and mitochondrial fractions and from ffie total
homogenates and 30 tg of total protein from nuclear fractions were analyzed by western
blots using antibodies agairist p53, Bax, Bd-2, cytochrome C and f3-actin. Upper panel:
representative images from four independent experiments are shown. Lower panel: relative
intensifies of pro- and anti-apoptotic proteins measured by western blots on ffie lysate,
cytosol, mitochondria and nuclei (shownftam teft to right). Values represent means ± S.D. of
triplicate experiments.Intensities of immuno-reactive bands are normalized for ffie intensifies
of f3-actin cross-reacfing bands on the same lanes. * p<O.001 as compared to mock-transfected
cefis.
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CONCLUSIONS AND PERSPECTIVES
The ubiquitin pathway is responsible for proteosome-mediated
turnover of short-lived regulatory proteins as well as the degradation of
misfolded, unassembled or damaged proteins that could 5e potentially
dangerous for the celi (Hochstrasser & Varshavsky, 1990; Varshavsky, 1997).
Ligation of activated ubiquitin to subsfrate proteins by ubiquitin protein
ligases, targets them to proteosomes or lysosomes where proteolysis occurs.
Previously, protein aggregation in ceils fransiently fransfected with
polyglutamine repeat-containing proteins was shown to directly cause near
complete inhibition of the ubiquffin-proteosome system (Bence et ai, 2001).
Our studies demonstrate that the impairment of the ubiquitin protein
degradation pathway also takes place in the ceils from LSD patients in which
the lysosomal protein degradation system is overwhelmed by undegraded
macromolecules.
We have shown that the expression of the most abundant cellular
ubiquitin C-terminal hydrolase, UCH-L1, is dramatically inhibited in ceils
from LSD patients including those affected with sialidosis, SIASD,
galactosialidosis, GM1-gangliosidosis, Morquio disease type A and B, and
Gaucher disease as weil as in normal fibroblasts in which accumulation of
lysosomal storage materials was induced by the cysteine protease inhibitor E
64. UCH-L1 was also inhibited in the brains of Sandhoff mice that showed
neuronal lysosomal storage and accumulation. UCH-L1 is especially
abundant in neurons and neuroendocrine celis where it represents 1-2% of
total soluble protein (Wilkinson et ai, 1989; Satoh & Kuroda, 2001a). Previous
studies have shown that UCH-L1 deficiency is involved in the pathogenesis
of several neurodegenerative disorders. In mice, mutation of the UCH-L1
gene resuits in gracile axonal dystrophy (GAD), a disorder characterized by
axonal degeneration of the gracile tract: the affected animals display sensory
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ataxia followed by posterior paralysis and death (Saigoh et ai, 1999).
Pathologicai examination of ffie GAD mice reveaied ubiquitinated inclusion
bodies, and dot-like deposits of proteosome immunoreactivity, indicating
deposits of proteosomai substrates; similar observations were made in
fransgenic mice in which the doubie-knockout UCH-L1 and UCH-L3 genes
resulted in posterior paralysis, dystrophic fleurons, and increased neuronal
death (Saïgoh et aI, 1999; Kurihara et ai, 2001). In Drosophila, genetic screens
have shown that an UCH homolog can enhance ataxia resuiting from abiation
of ataxin-1 ftmction (Femandez-Funez et ai, 2000). In humans, a missense
mutation (193M) in UCH-U has been linked to Parkinson’s disease. Further
studies have identified a S18Y poiymorphism in the UCH-L1 gene that is
iinked to decreased susceptibiity to Parkinson’s disease (Levecque et al, 2001;
Maraganore et al, 1999; Momose et ai, 2002; Satoh & Kuroda, 2001b; Wang et
ai, 2002; Liu et ai, 2002). Subsequent studies have shown that UCH-L1 also
cataiyses a reverse ubiquityl ligase activity which is sigrificantiy reduced by
a S18Y change (Liu et ai, 2002).
Ubiquitinated protein aggregates have been observed in tissues of
mice and humans affected with LSDs (Heuer et al, 2002; Higashi et ai, 1993;
Oya et ai, 199$; Zhan et ai, 1992), aithough Zhan et al (1992) viewed it as an
unspecific epiphenomenon rather than a mechanism of bioiogicai
significance. Our data suggest that infraceliular storage of ubiquitinated
aggregates seen in patients affected with LSDs is reiated to secondary UCH
Li deficiency, which also resuits in iower levels of free monomeric ubiquitin,
significantiy decreased proteosomal acfivity and increased apoptosis and
therefore confributes to tissue deterioration.
Previous studies have shown that ubiquitination is one of the major
mechanisms for the regulation of key proteins of the ceil apoptotic
machinery, such as p53 (Houpt et al., 1997) and the moiecules of Bci-2 family
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(reviewed in Lee and Peter, 2003; Yang and Yu, 2003). For example Ub
dependent degradation of pro-apoptofic Bd-2 family members Bid
(Breitschopf et al., 2000), Bax (Li and Dou, 2000) and Bak (Thomas and Banks,
1998) has been reported to promote ceil survival. Moreover, recent studies on
GAD and UCH-L3 knock-out mice suggest that through regulation of mUb
level, UCH-L1 plays a role in balancing the expression of pro- and anti
apoptotic proteins (Osaka et al., 2003; Kwon et al., 2004). The majority of
tumors and cancer celi mes contain significantly up-regulated UCH-L1 (Hibi
et al., 1998; Tezel et al., 2000, Yamazaki et al., 2002; Otsuki et al., 2004).
In this study, we showed that the fransient fransfection of celis with
UCH-L1 expression plasmid significantly reduced apoptosis in fibroblasts
freated with the lysosomal cysteine protease inhibitor E-64, whereas siRNA
induced inhibition of UCH-L1 expression caused apoptosis both in the
presence and in the absence of E-64. Almost 100% of siRNA-transfected ceils
were TUNEL-posifive and showed activated caspase cascade. Since the same
celis also showed presence of cytochrome C in the cytosol, and significantly
induced levels of Bax and p53, we suggest that the execution phase of
apoptosis involves transiocation of Bax to the mitochondrial membrane,
release of cytochrome C from the mitochondria and activation of the caspase
cascade.
Less clear is the development of the upstream events. Recent studies
(Osaka et al., 2003) have shown that UCH-L1 plays an important role in the
maintenance of the intracellular monoubiquitin (mlib) level either by
generating mUli through the hydrolysis of mono-ubiquitinated proteins
intended for lysosomal degradation or/and by binding mUb and thus
preventing its infra-lysosomal degradation (Fig. 24, p.85). In addition, the
use of inhibitors of lysosomal funcifon extended the Ub half-lffe and partially
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dimiuished the effect of UCH-L1, suggesting to Osaka et al. (2003) that UCH
Li may prevent ubiquitin degradation in lysosomes under normal conditions.
Shih et al. (2000) found that Ub contains ail the necessary signais for both
targeting and degradafion of monoubiquifflated proteins in the endosomai
lysosomal pathway. Therefore, direct UCH-L1 binding to Ub may prevent its
shunting to the endosomai-iysosomai pathway.
Under conditions of lysosomai storage though, the degradation of Ub
in the iysosome is also presumably impaired, as suggested by the observed
accumulation of ubiquitinated material in the lysosomal dense bodies. It is
tempting to speculate that down-regulation of UCH-L1 can be a part of
0
I
Cytochrome C release,
caspase activation
1
Apoptosis
FIGURE 24 Proposed scheme of UCH-L1-mediated apoptosis following lysosomal
storage.
A) In a normal ceil, sufficient lysosomal degradation maintains the recydling of mlibi in
conjuction with UCH-L1. UCH-L1 may prevent ubiquitin degradation in lysosome.
Proteasomal degradation of crifical cefi cycle and apoptosis regiilators is balanced.
B) In a ceil wiffi lysosomal storage, lysosomal function is impaired wiffi resulting intra
lysosomal accumulation of ubiquitin protein aggregates. Cellular mUbi levels drop and
are somehow sensed, resulting in a downregulation of UCH-L1 and deregulation of the
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ubiquitin-proteasome degradafion paffiway, driving the celi to apoptosis through ffie
mitochondrial paffiway.
the feedback mechanism to avoid a potential increase of the mUb level in the
cytoplasm. However, the reduction of UCH-L1 aiso suppresses deubiquili
nation of monoubiquitinated proteins before their degradation withÏn the
endosomal-lysosomai pathway and causes an opposite effect: the mUb
concentration in the ceil drops below the criticai level necessary to maintain
the proteosomai activity (fig. 24). Muitiubiquitinated proteins have a
propensity to aggregate and they have the potenfial to dkectiy block the
proteasome (Bence et ai, 2001). In other words, a vicious cycle probabiy starts
when accumulated proteins block the internai compartment of the
proteasome, thereby further reducing proteasomal activity and initiating the
celi death program. Aithough more experiments are needed to fuily conffrm
this hypothesis, we believe that our resuits might provide an expianation for
the increased apoptosis observed in many LSDs.
Interestingiy, in our gene microarrays (Table V), secreted-frizzled
related protein (SFRP1), dickkopf related protein-1 (DKK-1) and SOX-9, three
types of inhibitors of the Wnt signaling pathway, were ail significantly down
regulated in sialidosis skin fibroblasts compared to normais. Wnt signaling
piays a major role in celi fate determination through the reguiation of celi
proifferation, differentiation and apoptosis (Cadigan et ai, 1997). Recently,
SFRP1 was found to have a protective effect on cultured human fibroblasts by
decreasing the degree of ceramide-induced apoptosis (Xiaozhe et ai, 2003).
Moreover, in this same study, it was suggested that SFRP1 may reguiate
apoptosis through p53, caspases and bax (pro-apoptotic genes). Upon siRNA
inhibition of SFRP1, they observed a significant upreguiation of p53 and bax
aiong with activation of casp-9 and casp-3. Since degradation of (3-catenin
invoives the UPS, an impairment of UPS as in lysosomai storage, wouid cause
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a greater stabiity of f3-catenin. In the light of our UCH-L1 studies and our
microarray results showing SFRP1 downregulation, it is possible that both an
increase in [3-catenin signaling and UCH-L1 down-regulation hnpinge on the
same pathway (synergistic or additive effect), leading to the increased
apoptosis observed in lysosomal storage celis. The main issue that stili
remains probiematic in the studies pertaining to the fieid of LSDs is how
lysosomal storage can precisely engender changes in gene expression levels.
One valid ophiion would be that the endo-lysosomal pathway is perturbed
and that monoubiquitinated receptors on the celiular surface are flot properly
recycied, giving rise to a signal transduction cascade reaching the nucleus.
Taken together, our data suggest that decreased ubiquitin pathway
activity caused by secondary UCH-U deficiency contributes to cellular
deterioration in patients affected with LSDs. We propose that secondary
UCH-L1 deficiency in LSDs resuits in the infracellular storage of
ubiquitinated aggregates, lower levels of free monomeric ubiquitin,
signilicantly decreased proteosomal activity and increased apoptosis. In
confrast, fransient fransfection with a UCH-L1 expression plasmid
successfully reduced the prevaience of apoptosis in celis freated with the
lysosomal cysteine protease inhibitor E-64. On the other hand, siRNA
suppression of UCH-L1 in normal fibroblasts precipitated them to undergo
bax-mediated apoptosis. We believe that this mechanism provides a
reasonable explanation for the increased programmed celi death observed in
the different ceil and tissue types in almost ail LSDs regardless of the primary
genetic and biochemical defect. Since the apoptosis-related tissue
deterioration (including the neurodegeneration caused by the neuronal
apoptosis) is the underlying pathology in most LSDs, we believe that our
findings may help to develop new therapies that would target these
disorders.
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